k141_81212_2	CARD|gb|BAD59497.1|ARO:3000501|rpoB2	54.5	1221	1287	1162	0.0	1229
k141_81212_2	CARD|gb|WP_041777404.1|ARO:3004480|Bado_rpoB_RIF	52.6	1250	1287	1186	0.0	1181
k141_81212_2	megares|MEG_8674|Drugs|Rifampin|Rifampin-resistant_beta-subunit_of_RNA_polymerase_RpoB|RPOB_1	52.6	1250	1287	1186	0.0	1181
k141_81212_13	SARG|gi|502669352|ref|WP_012905216.1|	37.1	224	229	648	3.64e-38	139
k141_81212_13	SARG|gi|803568669|ref|WP_046077412.1|	35.5	220	229	648	3.83e-35	130
k141_81212_13	SARG|gi|446110352|ref|WP_000188207.1|	35.5	220	229	648	3.83e-35	130
k141_81212_13	SARG|YP_002382193	35.5	220	229	648	3.83e-35	130
k141_81212_13	SARG|gi|803575554|ref|WP_046081557.1|	35.5	220	229	648	3.83e-35	130
k141_81212_13	SARG|gi|446110351|ref|WP_000188206.1|	35.5	220	229	648	3.83e-35	130
k141_81212_13	SARG|gi|694064328|ref|WP_032410816.1|	33.8	222	229	646	1.65e-33	125
k141_81212_13	SARG|gi|736472622|ref|WP_034494292.1|	35.3	221	229	648	2.77e-32	122
k141_81212_13	SARG|gi|1035670474|ref|WP_064517458.1|	34.8	221	229	648	7.05e-32	121
k141_81212_13	SARG|gi|1035717981|ref|WP_064557480.1|	34.8	221	229	648	7.05e-32	121
k141_143970_2	SARG|gi|896325272|ref|WP_049294291.1|	26.5	445	438	648	1.48e-23	102
k141_143970_2	SARG|gi|639216333|ref|WP_024554080.1|	26.5	445	438	648	1.48e-23	102
k141_143970_2	SARG|gi|1001720867|ref|WP_061274204.1|	26.7	449	438	648	8.53e-23	100
k141_143970_2	SARG|gi|495736522|ref|WP_008461101.1|	26.7	449	438	648	1.14e-22	99.8
k141_143970_2	SARG|gi|746243059|ref|WP_039291473.1|	26.7	449	438	648	1.14e-22	99.8
k141_143970_2	SARG|gi|746253210|ref|WP_039301529.1|	26.7	449	438	648	1.14e-22	99.8
k141_143970_2	SARG|gi|1035670474|ref|WP_064517458.1|	26.1	449	438	648	2.04e-22	99.0
k141_143970_2	SARG|gi|1035717981|ref|WP_064557480.1|	26.1	449	438	648	2.04e-22	99.0
k141_143970_2	SARG|gi|736472622|ref|WP_034494292.1|	25.6	449	438	648	2.74e-22	98.6
k141_143970_2	SARG|gi|657888313|ref|WP_029592374.1|	26.1	445	438	648	4.89e-22	97.8
k141_143970_4	SARG|gi|555222481|ref|WP_023215070.1|	44.3	219	242	648	8.50e-61	201
k141_143970_4	SARG|gi|919601241|ref|WP_052893936.1|	43.8	219	242	648	1.19e-60	200
k141_143970_4	SARG|gi|959866458|ref|WP_058145168.1|	43.8	219	242	648	1.19e-60	200
k141_143970_4	SARG|ZP_03074747	43.8	219	242	648	1.19e-60	200
k141_143970_4	SARG|gi|555246906|ref|WP_023230855.1|	43.8	219	242	648	1.66e-60	200
k141_143970_4	SARG|YP_002044935	43.8	219	242	648	1.66e-60	200
k141_143970_4	SARG|gi|835666879|ref|WP_047606339.1|	43.8	219	242	648	1.66e-60	200
k141_143970_4	SARG|gi|685236936|ref|WP_031605176.1|	43.8	219	242	648	1.66e-60	200
k141_143970_4	SARG|gi|554958661|ref|WP_023203683.1|	43.8	219	242	648	1.66e-60	200
k141_143970_4	SARG|gi|446048043|ref|WP_000125898.1|	43.8	219	242	648	1.66e-60	200
k141_62860_12	CARD|gb|AEX49906.1|ARO:3003583|basS	25.5	271	722	477	1.39e-15	79.0
k141_62860_12	megares|MEG_7514|Drugs|Glycopeptide|VanL-type_regulator|VANSL_1	25.1	243	722	364	2.24e-13	71.2
k141_62860_12	NCBI|WP_063856745.1|1|1|vanS-L|vanS-L|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|glycopeptide_resistance_histidine_kinase_VanS-L|AMR|glycopeptide	25.1	243	722	364	2.24e-13	71.2
k141_62860_12	NCBI|WP_222891058.1|1|1|vanS-P|vanS-P|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|glycopeptide_resistance_histidine_kinase_VanS-P|AMR|glycopeptide	24.7	227	722	359	3.85e-13	70.5
k141_62860_12	NCBI|WP_003975349.1|1|1|vanS-Sc|vanS-Sc|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|glycopeptide_resistance_histidine_kinase_VanS-Sc|AMR|glycopeptide	26.3	232	722	364	2.24e-12	68.2
k141_62860_12	NCBI|WP_006285581.1|1|1|vanR-F|vanR-F|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|glycopeptide_resistance_response_regulator_transcription_factor_VanR-F|AMR|glycopeptide	32.5	120	722	231	1.37e-08	55.1
k141_62860_12	NCBI|WP_063856723.1|1|1|vanR-B|vanR-B|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|glycopeptide_resistance_response_regulator_transcription_factor_VanR-B|AMR|glycopeptide	33.6	116	722	219	9.50e-08	52.4
k141_62860_12	NCBI|WP_002317273.1|1|1|vanR-B|vanR-B|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|glycopeptide_resistance_response_regulator_transcription_factor_VanR-B|AMR|glycopeptide	33.6	116	722	219	9.50e-08	52.4
k141_62860_12	NCBI|WP_063856719.1|1|1|vanR-B|vanR-B|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|glycopeptide_resistance_response_regulator_transcription_factor_VanR-B|AMR|glycopeptide	33.6	116	722	220	9.61e-08	52.4
k141_62860_12	NCBI|WP_063856726.1|1|1|vanR-M|vanR-M|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|glycopeptide_resistance_response_regulator_transcription_factor_VanR-M|AMR|glycopeptide	34.2	117	722	232	2.67e-07	51.2
k141_51939_3	NCBI|WP_063856726.1|1|1|vanR-M|vanR-M|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|glycopeptide_resistance_response_regulator_transcription_factor_VanR-M|AMR|glycopeptide	44.7	226	230	232	8.83e-65	199
k141_51939_3	NCBI|WP_006285581.1|1|1|vanR-F|vanR-F|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|glycopeptide_resistance_response_regulator_transcription_factor_VanR-F|AMR|glycopeptide	42.8	229	230	231	6.12e-57	179
k141_51939_3	NCBI|AXB64454.1|1|1|vanR-Cd|vanR-Cd|re-structuring_of_the_cell_wall|1|VANCOMYCIN|GLYCOPEPTIDE|glycopeptide_resistance_response_regulator_transcription_factor_VanR-G-Cd|AMR|glycopeptide	37.1	229	230	233	1.90e-53	171
k141_51939_3	NCBI|WP_021418928.1|1|1|vanR-G|vanR-G|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|glycopeptide_resistance_response_regulator_transcription_factor_VanR-G|AMR|glycopeptide	37.7	231	230	235	1.14e-52	169
k141_51939_3	NCBI|WP_011461303.1|1|1|vanR-I|vanR-I|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|glycopeptide_resistance_response_regulator_transcription_factor_VanR-I|AMR|glycopeptide	37.7	228	230	232	2.96e-52	167
k141_51939_3	megares|MEG_7482|Drugs|Glycopeptide|VanL-type_regulator|VANRI_1	37.7	228	230	232	2.96e-52	167
k141_51939_3	NCBI|WP_001280781.1|1|1|vanR-A|vanR-A|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|glycopeptide_resistance_response_regulator_transcription_factor_VanR-A|AMR|glycopeptide	40.0	230	230	231	2.60e-50	162
k141_51939_3	NCBI|WP_063856721.1|1|1|vanR-A|vanR-A|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|glycopeptide_resistance_response_regulator_transcription_factor_VanR-A|AMR|glycopeptide	39.8	231	230	231	2.60e-50	162
k141_51939_3	megares|MEG_7449|Drugs|Glycopeptide|VanA-type_regulator|VANRA_1	39.8	231	230	231	1.47e-49	160
k141_51939_3	NCBI|WP_063856716.1|1|1|vanR-A|vanR-A|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|glycopeptide_resistance_response_regulator_transcription_factor_VanR-A|AMR|glycopeptide	39.8	231	230	231	1.47e-49	160
k141_159105_8	CARD|gb|AAN28945.1|ARO:3003785|Ctra_murA_FOF	32.6	427	421	444	1.77e-48	170
k141_11400_3	NCBI|WP_006285581.1|1|1|vanR-F|vanR-F|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|glycopeptide_resistance_response_regulator_transcription_factor_VanR-F|AMR|glycopeptide	46.5	226	232	231	1.05e-63	197
k141_11400_3	megares|MEG_4078|Drugs|Multi-drug_resistance|Multi-drug_RND_efflux_regulator|MTRAD_1	42.3	227	232	228	7.73e-63	194
k141_11400_3	NCBI|WP_063856726.1|1|1|vanR-M|vanR-M|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|glycopeptide_resistance_response_regulator_transcription_factor_VanR-M|AMR|glycopeptide	45.1	226	232	232	4.01e-61	190
k141_11400_3	NCBI|AXB64454.1|1|1|vanR-Cd|vanR-Cd|re-structuring_of_the_cell_wall|1|VANCOMYCIN|GLYCOPEPTIDE|glycopeptide_resistance_response_regulator_transcription_factor_VanR-G-Cd|AMR|glycopeptide	44.1	229	232	233	3.80e-59	185
k141_11400_3	NCBI|WP_011461303.1|1|1|vanR-I|vanR-I|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|glycopeptide_resistance_response_regulator_transcription_factor_VanR-I|AMR|glycopeptide	43.4	228	232	232	5.94e-58	182
k141_11400_3	megares|MEG_7482|Drugs|Glycopeptide|VanL-type_regulator|VANRI_1	43.8	224	232	232	1.19e-57	181
k141_11400_3	NCBI|WP_021418928.1|1|1|vanR-G|vanR-G|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|glycopeptide_resistance_response_regulator_transcription_factor_VanR-G|AMR|glycopeptide	42.4	231	232	235	1.30e-57	181
k141_11400_3	NCBI|WP_063856727.1|1|1|vanR-D|vanR-D|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|glycopeptide_resistance_response_regulator_transcription_factor_VanR-D|AMR|glycopeptide	42.6	230	232	232	7.67e-56	177
k141_11400_3	NCBI|WP_016295750.1|1|1|vanR-D|vanR-D|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|glycopeptide_resistance_response_regulator_transcription_factor_VanR-D|AMR|glycopeptide	42.6	230	232	232	1.09e-55	176
k141_11400_3	NCBI|WP_063856715.1|1|1|vanR-D|vanR-D|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|glycopeptide_resistance_response_regulator_transcription_factor_VanR-D|AMR|glycopeptide	42.6	230	232	232	2.17e-55	176
k141_11400_4	CARD|gb|ABD30512.1|ARO:3000839|arlS	31.5	232	597	451	2.21e-30	123
k141_11400_4	NCBI|WP_002305818.1|1|1|vanS-A|vanS-A|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|glycopeptide_resistance_histidine_kinase_VanS-A|AMR|glycopeptide	28.5	312	597	384	1.40e-26	110
k141_11400_4	megares|MEG_7454|Drugs|Glycopeptide|VanA-type_regulator|VANRA_1	28.5	312	597	384	1.40e-26	110
k141_11400_4	megares|MEG_7486|Drugs|Glycopeptide|VanA-type_regulator|VANSA_1	32.9	249	597	382	1.85e-26	110
k141_11400_4	NCBI|WP_063856731.1|1|1|vanS-A|vanS-A|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|glycopeptide_resistance_histidine_kinase_VanS-A|AMR|glycopeptide	32.9	249	597	382	1.85e-26	110
k141_11400_4	megares|MEG_7487|Drugs|Glycopeptide|VanA-type_regulator|VANSA_1	32.9	225	597	386	2.15e-25	107
k141_11400_4	NCBI|WP_063856740.1|1|1|vanS-Pt2|vanS-Pt2|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|glycopeptide_resistance_histidine_kinase_VanS-Pt2|AMR|glycopeptide	32.9	225	597	386	2.15e-25	107
k141_11400_4	NCBI|WP_063856741.1|1|1|vanS-Pt|vanS-Pt|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|glycopeptide_resistance_histidine_kinase_VanS-Pt|AMR|glycopeptide	32.9	234	597	386	3.92e-25	106
k141_11400_4	megares|MEG_7488|Drugs|Glycopeptide|VanA-type_regulator|VANSA_1	32.9	234	597	386	3.92e-25	106
k141_11400_4	NCBI|WP_063856742.1|1|1|vanS-Pt|vanS-Pt|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|glycopeptide_resistance_histidine_kinase_VanS-Pt|AMR|glycopeptide	32.5	234	597	388	2.41e-24	104
k141_11400_12	NCBI|WP_006285582.1|1|1|vanS-F|vanS-F|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|glycopeptide_resistance_histidine_kinase_VanS-F|AMR|glycopeptide	32.6	298	559	365	1.34e-25	107
k141_11400_12	NCBI|WP_063856748.1|1|1|vanS-M|vanS-M|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|glycopeptide_resistance_histidine_kinase_VanS-M|AMR|glycopeptide	31.5	273	559	370	2.39e-23	100
k141_11400_12	NCBI|AXB64455.1|1|1|vanS-Cd|vanS-Cd|re-structuring_of_the_cell_wall|1|VANCOMYCIN|GLYCOPEPTIDE|VanG-Cd-type_glycopeptide_resistance_histidine_kinase_VanS|AMR|glycopeptide	28.6	276	559	380	1.62e-22	98.6
k141_11400_12	megares|MEG_7498|Drugs|Glycopeptide|VanC-type_regulator|VANSC_1	28.6	276	559	380	1.62e-22	98.6
k141_11400_12	NCBI|WP_063856732.1|1|1|vanS-G|vanS-G|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|glycopeptide_resistance_histidine_kinase_VanS-G|AMR|glycopeptide	28.9	235	559	367	1.11e-21	95.9
k141_11400_12	NCBI|WP_021418927.1|1|1|vanS-G|vanS-G|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|glycopeptide_resistance_histidine_kinase_VanS-G|AMR|glycopeptide	28.9	235	559	368	1.13e-21	95.9
k141_11400_12	megares|MEG_7502|Drugs|Glycopeptide|VanC-type_regulator|VANSC_1	33.0	215	559	361	4.91e-20	90.9
k141_11400_12	NCBI|WP_063856733.1|1|1|vanS-C|vanS-C|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|glycopeptide_resistance_histidine_kinase_VanS-C|AMR|glycopeptide	33.0	215	559	361	4.91e-20	90.9
k141_11400_12	NCBI|WP_063856743.1|1|1|vanS-C|vanS-C|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|glycopeptide_resistance_histidine_kinase_VanS-C|AMR|glycopeptide	33.0	215	559	361	6.60e-20	90.5
k141_11400_12	megares|MEG_7499|Drugs|Glycopeptide|VanC-type_regulator|VANSC_1	33.0	215	559	361	6.60e-20	90.5
k141_11400_13	megares|MEG_7449|Drugs|Glycopeptide|VanA-type_regulator|VANRA_1	46.3	227	233	231	5.18e-72	218
k141_11400_13	NCBI|WP_063856716.1|1|1|vanR-A|vanR-A|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|glycopeptide_resistance_response_regulator_transcription_factor_VanR-A|AMR|glycopeptide	46.3	227	233	231	5.18e-72	218
k141_11400_13	NCBI|WP_011461303.1|1|1|vanR-I|vanR-I|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|glycopeptide_resistance_response_regulator_transcription_factor_VanR-I|AMR|glycopeptide	45.0	229	233	232	5.35e-72	218
k141_11400_13	megares|MEG_7482|Drugs|Glycopeptide|VanL-type_regulator|VANRI_1	45.0	229	233	232	5.35e-72	218
k141_11400_13	NCBI|WP_063856721.1|1|1|vanR-A|vanR-A|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|glycopeptide_resistance_response_regulator_transcription_factor_VanR-A|AMR|glycopeptide	45.4	227	233	231	2.40e-70	214
k141_11400_13	NCBI|WP_063856720.1|1|1|vanR-A|vanR-A|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|glycopeptide_resistance_response_regulator_transcription_factor_VanR-A|AMR|glycopeptide	45.4	227	233	231	3.40e-70	213
k141_11400_13	NCBI|WP_222891057.1|1|1|vanR-P|vanR-P|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|glycopeptide_resistance_response_regulator_transcription_factor_VanR-P|AMR|glycopeptide	46.1	232	233	239	4.38e-70	213
k141_11400_13	NCBI|AXB64454.1|1|1|vanR-Cd|vanR-Cd|re-structuring_of_the_cell_wall|1|VANCOMYCIN|GLYCOPEPTIDE|glycopeptide_resistance_response_regulator_transcription_factor_VanR-G-Cd|AMR|glycopeptide	44.8	230	233	233	5.89e-69	210
k141_11400_13	NCBI|WP_001280781.1|1|1|vanR-A|vanR-A|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|glycopeptide_resistance_response_regulator_transcription_factor_VanR-A|AMR|glycopeptide	44.5	227	233	231	1.57e-68	209
k141_11400_13	NCBI|WP_063856718.1|1|1|vanR-E|vanR-E|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|glycopeptide_resistance_response_regulator_transcription_factor_VanR-E|AMR|glycopeptide	43.7	229	233	229	1.69e-67	206
k141_140508_5	megares|MEG_5148|Drugs|beta-lactam|Class_D_betalactamases|OXA_1	56.6	53	181	346	1.95e-14	68.9
k141_546_3	megares|MEG_4309|Drugs|Multi-drug_resistance|Multi-drug_ABC_efflux_pumps|OPTRA_1	31.3	528	540	655	5.15e-79	259
k141_546_3	megares|MEG_4304|Drugs|Multi-drug_resistance|Multi-drug_ABC_efflux_pumps|OPTRA_1	31.1	528	540	655	7.20e-79	259
k141_546_3	SARG|gb|AKA86814|ARO:3003746|optrA	31.1	528	540	655	7.20e-79	259
k141_546_3	megares|MEG_4306|Drugs|Multi-drug_resistance|Multi-drug_ABC_efflux_pumps|OPTRA_1	31.3	528	540	655	1.41e-78	258
k141_546_3	megares|MEG_4313|Drugs|Multi-drug_resistance|Multi-drug_ABC_efflux_pumps|OPTRA_1	31.1	528	540	655	1.96e-78	258
k141_546_3	megares|MEG_4307|Drugs|Multi-drug_resistance|Multi-drug_ABC_efflux_pumps|OPTRA_1	31.1	528	540	655	1.96e-78	258
k141_546_3	megares|MEG_4312|Drugs|Multi-drug_resistance|Multi-drug_ABC_efflux_pumps|OPTRA_1	31.1	528	540	655	1.96e-78	258
k141_546_3	megares|MEG_4315|Drugs|Multi-drug_resistance|Multi-drug_ABC_efflux_pumps|OPTRA_1	31.1	528	540	655	1.96e-78	258
k141_546_3	megares|MEG_4318|Drugs|Multi-drug_resistance|Multi-drug_ABC_efflux_pumps|OPTRA_1	31.1	528	540	655	2.74e-78	258
k141_546_3	megares|MEG_4308|Drugs|Multi-drug_resistance|Multi-drug_ABC_efflux_pumps|OPTRA_1	31.1	528	540	655	2.74e-78	258
k141_546_5	SARG|gb|CAE00499.1|ARO:3003835|cdeA	37.6	434	444	441	1.60e-99	303
k141_81585_5	CARD|gb|ABD30512.1|ARO:3000839|arlS	30.5	325	464	451	1.01e-32	128
k141_81585_5	CARD|gb|AAD51347.1|ARO:3003067|smeS	27.7	300	464	467	5.22e-31	123
k141_81585_5	NCBI|WP_006285582.1|1|1|vanS-F|vanS-F|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|glycopeptide_resistance_histidine_kinase_VanS-F|AMR|glycopeptide	25.8	322	464	365	4.97e-29	116
k141_81585_5	NCBI|WP_011461302.1|1|1|vanS-I|vanS-I|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|glycopeptide_resistance_histidine_kinase_VanS-I|AMR|glycopeptide	29.7	249	464	392	3.13e-27	111
k141_81585_5	NCBI|AXB64455.1|1|1|vanS-Cd|vanS-Cd|re-structuring_of_the_cell_wall|1|VANCOMYCIN|GLYCOPEPTIDE|VanG-Cd-type_glycopeptide_resistance_histidine_kinase_VanS|AMR|glycopeptide	25.3	225	464	380	6.90e-25	104
k141_81585_5	megares|MEG_7498|Drugs|Glycopeptide|VanC-type_regulator|VANSC_1	25.3	225	464	380	6.90e-25	104
k141_81585_5	NCBI|WP_063856734.1|1|1|vanS-E|vanS-E|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|glycopeptide_resistance_histidine_kinase_VanS-E|AMR|glycopeptide	26.7	243	464	357	1.28e-24	103
k141_81585_5	megares|MEG_7511|Drugs|Glycopeptide|VanE-type_regulator|VANSE_1	26.7	243	464	357	1.28e-24	103
k141_81585_6	NCBI|WP_063856726.1|1|1|vanR-M|vanR-M|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|glycopeptide_resistance_response_regulator_transcription_factor_VanR-M|AMR|glycopeptide	46.0	226	230	232	5.75e-63	195
k141_81585_6	NCBI|AXB64454.1|1|1|vanR-Cd|vanR-Cd|re-structuring_of_the_cell_wall|1|VANCOMYCIN|GLYCOPEPTIDE|glycopeptide_resistance_response_regulator_transcription_factor_VanR-G-Cd|AMR|glycopeptide	46.7	229	230	233	2.39e-62	193
k141_81585_6	NCBI|WP_011461303.1|1|1|vanR-I|vanR-I|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|glycopeptide_resistance_response_regulator_transcription_factor_VanR-I|AMR|glycopeptide	46.5	228	230	232	3.74e-61	190
k141_81585_6	megares|MEG_7482|Drugs|Glycopeptide|VanL-type_regulator|VANRI_1	46.1	228	230	232	1.06e-60	189
k141_81585_6	NCBI|WP_005228837.1|1|1|vanR-C|vanR-C|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|glycopeptide_resistance_response_regulator_transcription_factor_VanR-C|AMR|glycopeptide	45.8	227	230	231	4.14e-60	187
k141_81585_6	NCBI|WP_063856722.1|1|1|vanR-D|vanR-D|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|glycopeptide_resistance_response_regulator_transcription_factor_VanR-D|AMR|glycopeptide	46.3	229	230	232	6.04e-60	187
k141_81585_6	NCBI|WP_063856724.1|1|1|vanR-L|vanR-L|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|glycopeptide_resistance_response_regulator_transcription_factor_VanR-L|AMR|glycopeptide	45.6	228	230	231	8.30e-60	187
k141_81585_6	NCBI|WP_006285581.1|1|1|vanR-F|vanR-F|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|glycopeptide_resistance_response_regulator_transcription_factor_VanR-F|AMR|glycopeptide	44.4	225	230	231	1.17e-59	186
k141_81585_6	NCBI|WP_021418928.1|1|1|vanR-G|vanR-G|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|glycopeptide_resistance_response_regulator_transcription_factor_VanR-G|AMR|glycopeptide	46.8	231	230	235	1.88e-59	186
k141_81585_6	megares|MEG_4078|Drugs|Multi-drug_resistance|Multi-drug_RND_efflux_regulator|MTRAD_1	44.2	226	230	228	2.15e-59	186
k141_77967_5	SARG|gb|BAG33043.1|ARO:3003920|pgpB	28.6	175	182	236	3.01e-09	53.5
k141_77967_5	megares|MEG_5776|Drugs|Lipopeptide|Lipid_A_phosphatase|PGBB_1	28.0	175	182	236	7.71e-09	52.4
k141_77967_14	SARG|gb|AAV85982.1|ARO:3000535|macB	30.8	201	252	644	5.68e-24	99.4
k141_77967_14	SARG|gi|694064328|ref|WP_032410816.1|	30.4	217	252	646	1.42e-23	98.2
k141_77967_14	SARG|gb|AAK76137.1|ARO:3000024|patA	30.6	216	252	564	3.61e-20	88.2
k141_77967_14	SARG|gb|AVI44920.1|ARO:3004470|poxtA	27.0	244	252	542	1.69e-13	68.6
k141_77967_14	NCBI|WP_209691075.1|1|1|poxtA2|poxtA|target_protection|2|CHLORAMPHENICOL/FLORFENICOL/LINEZOLID|OXAZOLIDINONE/PHENICOL|ABC-F_type_ribosomal_protection_protein_PoxtA2|AMR|multidrug	27.0	244	252	544	1.70e-13	68.6
k141_77967_14	SARG|gi|655401130|ref|WP_028800283.1|	28.9	180	252	599	1.77e-13	68.6
k141_77967_14	SARG|gi|930482089|ref|WP_054228897.1|	28.9	180	252	599	3.21e-13	67.8
k141_77967_14	SARG|gi|985844137|ref|WP_060895163.1|	28.9	180	252	599	3.21e-13	67.8
k141_77967_14	SARG|gi|501350226|ref|WP_012381861.1|	28.3	180	252	603	4.34e-13	67.4
k141_77967_14	SARG|gi|764446018|ref|WP_044369325.1|	27.8	180	252	605	5.85e-13	67.0
k141_77967_22	CARD|gb|AEX49906.1|ARO:3003583|basS	32.5	289	382	477	9.90e-28	112
k141_77967_22	SARG|gb|AAG05187.1|ARO:3005067|ParS	28.8	240	382	428	1.49e-24	103
k141_77967_22	CARD|gb|ADM92606.1|ARO:3000549|adeS	29.0	252	382	361	6.82e-22	94.7
k141_77967_22	megares|MEG_7514|Drugs|Glycopeptide|VanL-type_regulator|VANSL_1	30.4	217	382	364	3.84e-20	89.7
k141_77967_22	megares|MEG_7521|Drugs|Glycopeptide|VanN-type_regulator|VANSN_1	28.8	215	382	364	3.84e-20	89.7
k141_77967_22	NCBI|WP_063856745.1|1|1|vanS-L|vanS-L|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|glycopeptide_resistance_histidine_kinase_VanS-L|AMR|glycopeptide	30.4	217	382	364	3.84e-20	89.7
k141_77967_22	NCBI|WP_063856749.1|1|1|vanS-N|vanS-N|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|glycopeptide_resistance_histidine_kinase_VanS-N|AMR|glycopeptide	28.8	215	382	364	3.84e-20	89.7
k141_77967_22	NCBI|WP_222891058.1|1|1|vanS-P|vanS-P|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|glycopeptide_resistance_histidine_kinase_VanS-P|AMR|glycopeptide	25.7	206	382	359	1.04e-15	76.6
k141_77967_23	NCBI|WP_011029105.1|1|1|vanR-Sc|vanR-Sc|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|glycopeptide_resistance_response_regulator_transcription_factor_VanR-Sc|AMR|glycopeptide	40.1	222	226	231	7.25e-49	159
k141_77967_23	CARD|gb|ATC67679.1|ARO:3000838|arlR	38.8	219	226	219	1.45e-48	157
k141_77967_23	NCBI|WP_063856729.1|1|1|vanR-O|vanR-O|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|glycopeptide_resistance_response_regulator_transcription_factor_VanR-O|AMR|glycopeptide	38.2	225	226	233	3.07e-48	157
k141_77967_23	CARD|gb|SIP52035.1|ARO:3004054|Paer_CpxR	35.6	219	226	225	4.81e-39	133
k141_77967_23	NCBI|WP_063856723.1|1|1|vanR-B|vanR-B|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|glycopeptide_resistance_response_regulator_transcription_factor_VanR-B|AMR|glycopeptide	34.1	220	226	219	2.29e-38	131
k141_77967_23	NCBI|WP_002317273.1|1|1|vanR-B|vanR-B|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|glycopeptide_resistance_response_regulator_transcription_factor_VanR-B|AMR|glycopeptide	34.1	220	226	219	3.23e-38	131
k141_77967_23	NCBI|WP_063856719.1|1|1|vanR-B|vanR-B|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|glycopeptide_resistance_response_regulator_transcription_factor_VanR-B|AMR|glycopeptide	34.1	220	226	220	3.31e-38	131
k141_77967_23	NCBI|WP_032489743.1|1|1|vanR-B|vanR-B|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|glycopeptide_resistance_response_regulator_transcription_factor_VanR-B|AMR|glycopeptide	34.1	220	226	220	4.67e-38	130
k141_77967_23	NCBI|WP_002368697.1|1|1|vanR-B|vanR-B|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|glycopeptide_resistance_response_regulator_transcription_factor_VanR-B|AMR|glycopeptide	34.1	220	226	220	3.68e-37	128
k141_77967_23	SARG|ZP_02848503	33.6	220	226	221	5.89e-36	125
k141_77967_41	SARG|FJ872411.1.gene41.p01	37.1	348	360	352	4.16e-80	248
k141_77967_41	SARG|gi|498467695|ref|WP_010773051.1|	38.4	349	360	352	1.17e-79	246
k141_77967_41	SARG|AAR37060	40.4	356	360	343	3.57e-79	245
k141_77967_41	SARG|AF277571.gene.p01	39.9	356	360	343	2.01e-78	243
k141_77967_41	SARG|gi|511041762|ref|WP_016295754.1|	39.6	356	360	343	5.66e-78	242
k141_77967_41	SARG|DQ212986.1.gene8.p01	38.2	351	360	349	2.70e-77	240
k141_77967_41	SARG|gi|696673086|ref|WP_033144146.1|	39.6	356	360	343	3.19e-77	240
k141_77967_41	SARG|gi|405945042|pdb|4FU0|A	38.2	351	360	357	3.41e-77	240
k141_77967_41	SARG|BAE96117	39.6	356	360	343	4.50e-77	239
k141_77967_41	SARG|gi|765411304|ref|WP_044689514.1|	38.2	351	360	349	5.38e-77	239
k141_81707_25	megares|MEG_5396|Drugs|Aminocoumarins|Aminocoumarin-resistant_DNA_topoisomerases|PARY_1	39.0	236	259	703	7.79e-44	156
k141_18889_8	SARG|YP_002333394	37.1	251	318	323	8.96e-38	135
k141_18889_8	SARG|AF310956.2.gene5.p01	36.7	251	318	323	3.42e-37	134
k141_18889_8	NCBI|WP_063856701.1|1|1|vanH-B|vanH-B|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|D-lactate_dehydrogenase_VanH-B|AMR|glycopeptide	36.7	251	318	323	3.42e-37	134
k141_18889_8	SARG|gi|552942232|ref|WP_023043160.1|	36.5	255	318	323	9.35e-37	133
k141_18889_8	SARG|AAY52004	35.3	255	318	322	2.50e-36	132
k141_18889_8	SARG|gi|749574782|ref|WP_040203616.1|	34.5	255	318	323	2.55e-36	132
k141_18889_8	SARG|AAD51059	34.9	255	318	323	4.98e-36	131
k141_18889_8	SARG|CAB61228	35.9	251	318	322	6.81e-36	130
k141_18889_8	SARG|AY082011.1.gene6.p01	36.1	255	318	323	6.95e-36	130
k141_18889_8	SARG|AAD41881	34.9	255	318	323	9.71e-36	130
k141_67051_2	SARG|gi|1004359922|gb|AMP42228.1|	26.2	435	605	639	3.32e-26	112
k141_67051_2	SARG|AAO42740	26.4	435	605	639	5.89e-26	111
k141_67051_2	SARG|AY485126.gene.p01	26.4	435	605	639	5.89e-26	111
k141_67051_2	megares|MEG_7175|Drugs|Tetracycline|Tetracycline_resistance_ribosomal_protection_proteins|TETO_1	26.4	435	605	639	5.89e-26	111
k141_67051_2	megares|MEG_7169|Drugs|Tetracycline|Tetracycline_resistance_ribosomal_protection_proteins|TETO_1	26.4	435	605	629	7.58e-26	111
k141_67051_2	megares|MEG_7170|Drugs|Tetracycline|Tetracycline_resistance_ribosomal_protection_proteins|TETO_1	26.4	435	605	629	7.58e-26	111
k141_67051_2	ResF|tet(O/W)_3_AM889120_1	26.4	435	605	639	7.83e-26	111
k141_67051_2	ResF|tet(O/W)_4_AM889121_1	26.4	435	605	639	7.83e-26	111
k141_67051_2	SARG|ABN79417	26.2	435	605	639	1.04e-25	110
k141_67051_2	megares|MEG_7163|Drugs|Tetracycline|Tetracycline_resistance_ribosomal_protection_proteins|TETO_1	26.4	435	605	629	1.34e-25	110
k141_67051_7	SARG|gb|ADZ12699.1|ARO:3005091|RanA	27.8	237	237	258	7.72e-24	95.1
k141_107663_1	SARG|gb|WP_104671188.1|ARO:3003948|efrA	38.3	553	562	575	2.28e-119	363
k141_107663_1	SARG|gb|AAK76137.1|ARO:3000024|patA	38.0	523	562	564	9.10e-109	335
k141_107663_1	SARG|gi|948137056|ref|WP_056795395.1|	32.2	550	562	602	1.32e-81	266
k141_107663_1	SARG|gi|926351744|ref|WP_053683383.1|	31.4	560	562	648	2.00e-80	264
k141_107663_1	SARG|gi|493394434|ref|WP_006350564.1|	31.0	555	562	602	2.72e-80	262
k141_107663_1	SARG|gi|516795764|ref|WP_018105258.1|	31.6	545	562	601	5.20e-80	261
k141_107663_1	SARG|gi|926400371|ref|WP_053728483.1|	31.1	550	562	603	7.63e-80	261
k141_107663_1	SARG|gi|739906046|ref|WP_037756452.1|	31.6	550	562	620	1.12e-79	261
k141_107663_1	SARG|gi|917229923|ref|WP_051836635.1|	32.5	548	562	620	1.12e-79	261
k141_107663_1	SARG|gi|497748188|ref|WP_010062372.1|	31.6	548	562	605	3.06e-79	259
k141_107663_2	SARG|gb|AAK76136.1|ARO:3000025|patB	41.7	503	607	588	1.25e-122	374
k141_107663_2	SARG|gb|AYV52072.1|ARO:3002882|lmrD	38.0	524	607	664	1.04e-114	355
k141_107663_2	SARG|gb|AAC74000.1|ARO:3003950|msbA	34.3	583	607	582	2.60e-97	308
k141_107663_2	SARG|gi|928900436|ref|WP_053931243.1|	35.6	492	607	600	3.01e-92	295
k141_107663_2	SARG|gi|664579989|ref|WP_031094015.1|	35.6	492	607	601	3.09e-92	295
k141_107663_2	NCBI|WP_289811733.1|1|1|tetB(60)|tetB(60)||2|TETRACYCLINE|TETRACYCLINE|tetracycline_efflux_ABC_transporter_Tet(60)_subunit_B|AMR|tetracycline	34.2	585	607	579	1.34e-91	293
k141_107663_2	SARG|gi|944009777|ref|WP_055601444.1|	35.0	494	607	628	3.28e-91	293
k141_107663_2	SARG|gi|948137056|ref|WP_056795395.1|	34.6	492	607	602	1.31e-90	291
k141_107663_2	SARG|gb|ANZ79241.1|ARO:3004036|tetB(60)	34.4	585	607	579	1.44e-90	290
k141_107663_2	SARG|gi|921231571|ref|WP_053176464.1|	34.3	507	607	620	4.01e-90	290
k141_170689_2	SARG|L42544.gene.p01	28.7	359	611	651	3.56e-31	127
k141_170689_2	SARG|AAV80410	28.7	359	611	651	3.56e-31	127
k141_170689_2	SARG|gi|658130997|emb|CDO19407.1|	25.9	464	611	644	2.67e-29	122
k141_170689_2	SARG|YP_001834888	25.3	463	611	644	3.56e-29	121
k141_170689_2	SARG|gi|294769543|gb|ADF36620.1|	25.6	464	611	644	8.46e-29	120
k141_170689_2	SARG|YP_001694718	25.2	456	611	639	1.97e-28	119
k141_170689_2	SARG|CAR69107	25.2	456	611	639	1.97e-28	119
k141_170689_2	SARG|gi|291587251|gb|ADE19326.1|	25.4	464	611	644	2.01e-28	119
k141_170689_2	SARG|AAY63943	25.2	456	611	639	2.63e-28	119
k141_170689_2	SARG|gi|538450536|ref|WP_020998529.1|	25.2	456	611	639	2.63e-28	119
k141_19324_13	NCBI|XSG12258.1|1|1|drcS|drcS||1|||daptomycin_efflux_sensor_histidine_kinase_DrcS|AMR|peptide	25.5	243	575	341	2.28e-07	52.0
k141_170763_4	megares|MEG_3786|Drugs|beta-lactam|Penicillin_binding_protein|MECA_1	26.3	213	696	585	6.66e-14	73.9
k141_170763_4	NCBI|WP_000952923.1|1|1|mecR1|mecR1|regulation|2|METHICILLIN|beta-lactam|beta-lactam_sensor/signal_transducer_MecR1|AMR|beta-lactam	26.3	213	696	585	6.66e-14	73.9
k141_133641_2	SARG|gb|CAE00499.1|ARO:3003835|cdeA	29.0	428	454	441	2.57e-45	162
k141_170905_6	NCBI|WP_002389535.1|1|1|bcrA_Lm|bcrA_Lm||2|peptide|peptide|peptide_resistance_ABC_transporter_ATP-binding_subunit_BcrA|AMR|peptide	28.0	211	250	307	3.75e-18	80.9
k141_170905_6	SARG|gi|912614197|ref|WP_050196089.1|	29.0	214	250	648	5.29e-14	70.1
k141_170905_6	SARG|gi|171851258|emb|CAQ04234.1|	37.0	100	250	483	7.49e-07	48.5
k141_170905_6	SARG|gi|736993687|ref|WP_034989673.1|	39.0	77	250	513	1.84e-06	47.4
k141_170905_6	SARG|AF024666.2.gene6.p01	39.0	77	250	513	1.84e-06	47.4
k141_149246_3	NCBI|WP_063856748.1|1|1|vanS-M|vanS-M|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|glycopeptide_resistance_histidine_kinase_VanS-M|AMR|glycopeptide	27.9	283	742	370	6.16e-29	118
k141_149246_3	NCBI|WP_006285582.1|1|1|vanS-F|vanS-F|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|glycopeptide_resistance_histidine_kinase_VanS-F|AMR|glycopeptide	27.9	276	742	365	4.63e-28	115
k141_149246_3	NCBI|AXB64455.1|1|1|vanS-Cd|vanS-Cd|re-structuring_of_the_cell_wall|1|VANCOMYCIN|GLYCOPEPTIDE|VanG-Cd-type_glycopeptide_resistance_histidine_kinase_VanS|AMR|glycopeptide	26.0	285	742	380	2.29e-25	107
k141_149246_3	megares|MEG_7498|Drugs|Glycopeptide|VanC-type_regulator|VANSC_1	26.0	285	742	380	2.29e-25	107
k141_149246_3	megares|MEG_7514|Drugs|Glycopeptide|VanL-type_regulator|VANSL_1	27.4	259	742	364	1.57e-23	102
k141_149246_3	NCBI|WP_063856745.1|1|1|vanS-L|vanS-L|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|glycopeptide_resistance_histidine_kinase_VanS-L|AMR|glycopeptide	27.4	259	742	364	1.57e-23	102
k141_149246_3	NCBI|WP_023042297.1|1|1|vanS-D|vanS-D|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|glycopeptide_resistance_histidine_kinase_VanS-D|AMR|glycopeptide	24.8	258	742	381	3.57e-23	101
k141_149246_3	megares|MEG_7509|Drugs|Glycopeptide|VanD-type_regulator|VANSD_1	24.8	258	742	381	3.57e-23	101
k141_149246_3	NCBI|WP_063856744.1|1|1|vanS-D|vanS-D|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|glycopeptide_resistance_histidine_kinase_VanS-D|AMR|glycopeptide	27.5	229	742	381	8.66e-23	100
k141_149246_3	megares|MEG_7504|Drugs|Glycopeptide|VanD-type_regulator|VANSD_1	27.5	229	742	381	8.66e-23	100
k141_149246_4	NCBI|WP_011461303.1|1|1|vanR-I|vanR-I|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|glycopeptide_resistance_response_regulator_transcription_factor_VanR-I|AMR|glycopeptide	48.3	230	232	232	2.76e-74	224
k141_149246_4	megares|MEG_7482|Drugs|Glycopeptide|VanL-type_regulator|VANRI_1	48.3	230	232	232	2.76e-74	224
k141_149246_4	NCBI|WP_021418928.1|1|1|vanR-G|vanR-G|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|glycopeptide_resistance_response_regulator_transcription_factor_VanR-G|AMR|glycopeptide	48.5	231	232	235	8.65e-74	223
k141_149246_4	NCBI|WP_222891057.1|1|1|vanR-P|vanR-P|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|glycopeptide_resistance_response_regulator_transcription_factor_VanR-P|AMR|glycopeptide	46.6	232	232	239	7.40e-71	215
k141_149246_4	megares|MEG_7449|Drugs|Glycopeptide|VanA-type_regulator|VANRA_1	46.3	227	232	231	1.63e-70	214
k141_149246_4	NCBI|WP_063856716.1|1|1|vanR-A|vanR-A|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|glycopeptide_resistance_response_regulator_transcription_factor_VanR-A|AMR|glycopeptide	46.3	227	232	231	1.63e-70	214
k141_149246_4	NCBI|AXB64454.1|1|1|vanR-Cd|vanR-Cd|re-structuring_of_the_cell_wall|1|VANCOMYCIN|GLYCOPEPTIDE|glycopeptide_resistance_response_regulator_transcription_factor_VanR-G-Cd|AMR|glycopeptide	47.4	230	232	233	2.47e-70	214
k141_149246_4	NCBI|WP_001280781.1|1|1|vanR-A|vanR-A|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|glycopeptide_resistance_response_regulator_transcription_factor_VanR-A|AMR|glycopeptide	46.7	227	232	231	9.34e-70	212
k141_149246_4	NCBI|WP_063856720.1|1|1|vanR-A|vanR-A|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|glycopeptide_resistance_response_regulator_transcription_factor_VanR-A|AMR|glycopeptide	45.8	227	232	231	3.77e-69	211
k141_149246_4	NCBI|WP_063856721.1|1|1|vanR-A|vanR-A|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|glycopeptide_resistance_response_regulator_transcription_factor_VanR-A|AMR|glycopeptide	45.4	227	232	231	7.56e-69	210
k141_60439_2	SARG|gb|ADZ12699.1|ARO:3005091|RanA	33.7	246	526	258	3.76e-32	123
k141_60439_2	NCBI|XSG12260.1|1|1|drcA|drcA||1|||daptomycin_efflux_ABC_transporter_ATP-binding_protein_DrcA|AMR|peptide	32.4	222	526	255	9.83e-29	113
k141_60439_2	SARG|gi|694064328|ref|WP_032410816.1|	36.4	220	526	646	1.92e-25	109
k141_60439_2	SARG|gb|AYV52072.1|ARO:3002882|lmrD	29.4	228	526	664	3.47e-22	99.4
k141_60439_2	SARG|gb|WP_104671188.1|ARO:3003948|efrA	26.1	234	526	575	2.06e-20	93.6
k141_60439_2	SARG|gb|AAK76136.1|ARO:3000025|patB	27.6	228	526	588	3.77e-20	92.8
k141_60439_2	SARG|gi|817122037|ref|WP_046494699.1|	29.5	234	526	613	1.15e-17	85.1
k141_60439_2	SARG|AF170880.4.gene1.p01	31.6	231	526	615	1.16e-17	85.1
k141_60439_2	SARG|gi|558888514|ref|WP_023543283.1|	31.6	231	526	615	1.54e-17	84.7
k141_60439_2	SARG|gi|748767925|ref|WP_040019608.1|	30.4	230	526	623	4.82e-17	83.2
k141_42060_13	CARD|gb|AAC75429.1|ARO:3000833|evgS	33.2	374	684	1197	2.95e-46	176
k141_42060_13	megares|MEG_7514|Drugs|Glycopeptide|VanL-type_regulator|VANSL_1	29.8	235	684	364	3.34e-23	100
k141_42060_13	NCBI|WP_063856745.1|1|1|vanS-L|vanS-L|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|glycopeptide_resistance_histidine_kinase_VanS-L|AMR|glycopeptide	29.8	235	684	364	3.34e-23	100
k141_42060_13	NCBI|WP_222891058.1|1|1|vanS-P|vanS-P|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|glycopeptide_resistance_histidine_kinase_VanS-P|AMR|glycopeptide	28.7	237	684	359	4.21e-18	85.5
k141_42060_13	CARD|gb|AEX49906.1|ARO:3003583|basS	26.6	244	684	477	1.69e-15	78.6
k141_42060_13	CARD|gb|ATC67679.1|ARO:3000838|arlR	37.9	116	684	219	4.03e-13	68.2
k141_42060_13	CARD|gb|AAG06465.1|ARO:3005063|cprR	33.3	114	684	223	5.83e-13	67.8
k141_42060_13	NCBI|WP_006285581.1|1|1|vanR-F|vanR-F|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|glycopeptide_resistance_response_regulator_transcription_factor_VanR-F|AMR|glycopeptide	30.6	121	684	231	1.81e-11	63.5
k141_42060_13	CARD|gb|ADM92605.1|ARO:3000553|adeR	35.9	117	684	247	1.00e-10	61.6
k141_42060_13	NCBI|WP_063856726.1|1|1|vanR-M|vanR-M|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|glycopeptide_resistance_response_regulator_transcription_factor_VanR-M|AMR|glycopeptide	30.8	107	684	232	1.30e-08	55.1
k141_149453_4	NCBI|WP_005813024.1|1|1|vanW-I|vanW-I||2|VANCOMYCIN|GLYCOPEPTIDE|glycopeptide_resistance_accessory_protein_VanW-I|AMR|glycopeptide	28.2	330	521	373	4.50e-24	102
k141_76072_8	CARD|gb|WKR28567.1|ARO:3007678|IreK	46.3	268	812	718	2.24e-71	247
k141_76072_13	SARG|B1LLK9	30.0	293	310	660	9.28e-36	135
k141_76072_13	SARG|gi|489117806|ref|WP_003027650.1|	31.4	293	310	660	9.28e-36	135
k141_76072_13	SARG|gi|696375142|ref|WP_032949690.1|	31.4	293	310	660	1.27e-35	134
k141_76072_13	SARG|gi|754613472|ref|WP_042002901.1|	30.0	293	310	660	1.73e-35	134
k141_76072_13	SARG|gi|765458296|ref|WP_044714032.1|	31.4	293	310	660	1.73e-35	134
k141_76072_13	SARG|gi|692997842|ref|WP_032184680.1|	30.0	293	310	660	2.37e-35	134
k141_76072_13	SARG|gi|735685540|ref|WP_034173220.1|	30.0	293	310	660	2.37e-35	134
k141_76072_13	SARG|gi|851965596|ref|WP_048234849.1|	31.4	293	310	660	2.37e-35	134
k141_76072_13	SARG|gi|486385683|ref|WP_001600222.1|	30.0	293	310	660	2.37e-35	134
k141_76072_13	SARG|gi|486392102|ref|WP_001603016.1|	30.0	293	310	660	2.37e-35	134
k141_119707_2	SARG|gi|1035706844|ref|WP_064548272.1|	37.7	77	954	648	1.61e-08	57.4
k141_97688_1	SARG|YP_002333394	34.1	302	327	323	1.72e-51	172
k141_97688_1	SARG|DQ018711.1.gene4.p01	32.4	309	327	322	1.41e-49	167
k141_97688_1	SARG|gi|737310392|ref|WP_035293250.1|	32.0	309	327	323	1.11e-48	164
k141_97688_1	SARG|gi|740152780|ref|WP_037997109.1|	33.0	309	327	322	8.36e-48	162
k141_97688_1	NCBI|WP_063856705.1|1|1|vanH-D|vanH-D|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|D-lactate_dehydrogenase_VanH-D|AMR|glycopeptide	32.3	300	327	323	8.57e-48	162
k141_97688_1	SARG|gi|746609237|ref|WP_039635344.1|	32.8	302	327	322	1.17e-47	162
k141_97688_1	SARG|AAR37059	31.7	315	327	323	1.69e-47	161
k141_97688_1	SARG|gi|749574782|ref|WP_040203616.1|	31.5	302	327	323	3.34e-47	160
k141_97688_1	SARG|AAD51059	31.7	303	327	323	4.69e-47	160
k141_97688_1	SARG|AAD41881	32.0	303	327	323	4.69e-47	160
k141_97688_48	NCBI|XSG12260.1|1|1|drcA|drcA||1|||daptomycin_efflux_ABC_transporter_ATP-binding_protein_DrcA|AMR|peptide	40.5	195	203	255	9.02e-40	135
k141_97688_48	SARG|gi|1032819400|ref|WP_064325534.1|	39.7	199	203	646	3.13e-35	129
k141_97688_48	SARG|gi|498115003|ref|WP_010429159.1|	39.2	199	203	646	8.05e-35	128
k141_97688_48	SARG|gi|974588181|ref|WP_059178476.1|	38.5	195	203	646	3.89e-34	126
k141_97688_48	SARG|gi|969848384|ref|WP_058609247.1|	38.7	199	203	646	3.89e-34	126
k141_97688_48	SARG|YP_001176128	38.5	195	203	646	3.89e-34	126
k141_97688_48	SARG|gi|493171912|ref|WP_006174388.1|	38.7	199	203	646	3.89e-34	126
k141_97688_48	SARG|gi|895898290|ref|WP_048999361.1|	38.7	199	203	646	3.89e-34	126
k141_97688_48	SARG|gi|654544841|ref|WP_028012549.1|	38.7	199	203	646	5.33e-34	126
k141_97688_48	SARG|gi|695731408|ref|WP_032657917.1|	38.7	199	203	646	5.33e-34	126
k141_123938_3	NCBI|XSG12260.1|1|1|drcA|drcA||1|||daptomycin_efflux_ABC_transporter_ATP-binding_protein_DrcA|AMR|peptide	26.5	200	239	255	5.58e-18	79.3
k141_123938_3	SARG|gb|AAA26793|ARO:3003748|oleC	24.5	216	239	325	3.27e-12	63.9
k141_123938_3	megares|MEG_4276|Drugs|MLS|MLS_resistance_ABC_efflux_pumps|OLEC_1	24.5	216	239	325	3.27e-12	63.9
k141_123938_3	NCBI|WP_171943877.1|1|1|vga(F)|vga(F)|target_protection|2|LINCOSAMIDE|LINCOSAMIDE|ABC-F_type_ribosomal_protection_protein_Vga(F)|AMR|lincosamide	27.7	173	239	461	4.28e-09	55.1
k141_123938_3	NCBI|WP_172065992.1|1|1|vga(F)|vga(F)|target_protection|2|LINCOSAMIDE|LINCOSAMIDE|ABC-F_type_ribosomal_protection_protein_Vga(F)|AMR|lincosamide	28.3	173	239	461	1.40e-08	53.5
k141_64737_7	SARG|gi|445996719|ref|WP_000074574.1|	27.1	210	503	309	1.43e-13	70.5
k141_64737_7	SARG|gi|445996710|ref|WP_000074565.1|	26.6	214	503	309	2.58e-13	69.7
k141_64737_7	SARG|gi|445996722|ref|WP_000074577.1|	27.1	210	503	309	4.64e-13	68.9
k141_64737_7	SARG|gi|445996723|ref|WP_000074578.1|	27.1	210	503	309	6.23e-13	68.6
k141_64737_7	SARG|gi|445996729|ref|WP_000074584.1|	26.2	214	503	309	8.35e-13	68.2
k141_64737_7	SARG|gi|895736250|emb|COF64653.1|	26.2	214	503	309	8.35e-13	68.2
k141_64737_7	SARG|gi|446110087|ref|WP_000187942.1|	26.2	214	503	309	8.35e-13	68.2
k141_64737_7	SARG|gi|445996724|ref|WP_000074579.1|	26.7	210	503	309	1.12e-12	67.8
k141_64737_7	SARG|gi|445996714|ref|WP_000074569.1|	26.7	210	503	309	1.12e-12	67.8
k141_64737_7	SARG|gi|1043490477|ref|WP_065382463.1|	26.7	210	503	309	1.50e-12	67.4
k141_175295_6	megares|MEG_5396|Drugs|Aminocoumarins|Aminocoumarin-resistant_DNA_topoisomerases|PARY_1	44.0	679	634	703	4.37e-171	503
k141_61113_6	SARG|gi|835503090|ref|WP_047529730.1|	28.4	148	151	139	4.83e-08	48.1
k141_61113_6	SARG|gi|835313446|ref|WP_047449523.1|	28.4	148	151	139	4.83e-08	48.1
k141_61113_6	SARG|gi|678263223|emb|CDR66934.1|	27.7	148	151	172	2.02e-07	47.0
k141_61113_6	NCBI|WP_002437790.1|1|1|fosB-Sepi|fosB-Sepi|thiol_transferase|2|phosphonic	26.5	147	151	142	3.63e-07	45.8
k141_61113_6	SARG|Q55317	28.4	148	151	139	6.69e-07	45.1
k141_61113_6	SARG|gi|515489106|ref|WP_016922374.1|	28.4	148	151	139	9.27e-07	44.7
k141_61113_6	SARG|gi|835263828|ref|WP_047425942.1|	27.7	148	151	139	1.29e-06	44.3
k141_61113_6	SARG|gi|488321803|ref|WP_002391188.1|	28.4	148	151	139	1.78e-06	43.9
k141_61113_6	SARG|gb|ALM24145.1|ARO:3004673|FosB6	27.0	148	151	139	1.78e-06	43.9
k141_61113_6	SARG|Q03377	27.7	148	151	139	3.41e-06	43.1
k141_61113_8	SARG|M55620.gene.p01	43.9	212	225	219	3.74e-67	205
k141_61113_8	NCBI|WP_063843221.1|1|1|catA16|catA16|acetyltransferase|2|CHLORAMPHENICOL|PHENICOL|type_A-16_phenicol_O-acetyltransferase_CatQ|AMR|phenicol	43.9	212	225	219	7.51e-67	204
k141_61113_8	SARG|YP_001310303	44.3	210	225	219	1.22e-65	201
k141_61113_8	SARG|M93113.gene.p01	43.8	210	225	219	1.40e-64	198
k141_61113_8	SARG|M35190.gene.p01	48.5	200	225	207	2.21e-63	195
k141_61113_8	SARG|gi|505206451|ref|WP_015393553.1|	44.3	210	225	219	2.27e-63	195
k141_61113_8	NCBI|WP_043774378.1|1|1|catA13|catA13|acetyltransferase|2|CHLORAMPHENICOL|PHENICOL|type_A-13_phenicol_O-acetyltransferase|AMR|phenicol	49.0	200	225	207	3.13e-63	194
k141_61113_8	SARG|YP_001144149	49.0	200	225	208	3.23e-63	194
k141_61113_8	SARG|X15100.gene.p01	46.3	205	225	212	8.42e-62	191
k141_61113_8	SARG|AF226276.1.gene3.p01	46.1	204	225	207	1.45e-61	190
k141_83225_2	NCBI|WP_063856862.1|1|1|vanY-D|vanY-D|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|transpeptidase-like_D-Ala-D-Ala_carboxypeptidase_VanY-D|AMR|glycopeptide	27.7	256	389	356	2.07e-14	72.8
k141_83225_2	NCBI|WP_049898469.1|1|1|vanY-D|vanY-D|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|transpeptidase-like_D-Ala-D-Ala_carboxypeptidase_VanY-D|AMR|glycopeptide	28.1	256	389	356	2.78e-14	72.4
k141_72473_1	SARG|gb|AAK76137.1|ARO:3000024|patA	38.2	55	69	564	3.92e-09	49.7
k141_72473_1	SARG|gb|NP_388442.1|ARO:3004476|vmlR	47.8	46	69	547	7.32e-09	48.9
k141_72473_1	SARG|gi|851922185|ref|WP_048218206.1|	43.9	57	69	648	7.37e-09	48.9
k141_72473_1	SARG|gi|949718947|ref|WP_057063453.1|	43.9	57	69	648	7.37e-09	48.9
k141_72473_1	SARG|gi|696375069|ref|WP_032949617.1|	43.9	57	69	648	7.37e-09	48.9
k141_72473_1	SARG|gi|489127020|ref|WP_003036815.1|	43.9	57	69	648	7.37e-09	48.9
k141_72473_1	SARG|gi|936194420|ref|WP_054528571.1|	43.9	57	69	648	1.89e-08	47.8
k141_72473_1	SARG|gi|696368937|ref|WP_032943949.1|	43.9	57	69	648	1.89e-08	47.8
k141_72473_1	SARG|gi|851913025|ref|WP_048215946.1|	43.9	57	69	648	1.89e-08	47.8
k141_72473_1	SARG|YP_002850060	43.9	57	69	648	1.89e-08	47.8
k141_127444_6	NCBI|WP_063856722.1|1|1|vanR-D|vanR-D|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|glycopeptide_resistance_response_regulator_transcription_factor_VanR-D|AMR|glycopeptide	39.4	94	167	232	5.74e-22	87.4
k141_127444_6	NCBI|AXB64454.1|1|1|vanR-Cd|vanR-Cd|re-structuring_of_the_cell_wall|1|VANCOMYCIN|GLYCOPEPTIDE|glycopeptide_resistance_response_regulator_transcription_factor_VanR-G-Cd|AMR|glycopeptide	41.1	95	167	233	8.20e-22	87.0
k141_127444_6	NCBI|WP_021418928.1|1|1|vanR-G|vanR-G|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|glycopeptide_resistance_response_regulator_transcription_factor_VanR-G|AMR|glycopeptide	36.7	98	167	235	2.34e-21	85.9
k141_127444_6	NCBI|WP_063856724.1|1|1|vanR-L|vanR-L|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|glycopeptide_resistance_response_regulator_transcription_factor_VanR-L|AMR|glycopeptide	39.8	88	167	231	4.26e-21	85.1
k141_127444_6	NCBI|WP_063856728.1|1|1|vanR-N|vanR-N|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|glycopeptide_resistance_response_regulator_transcription_factor_VanR-N|AMR|glycopeptide	40.9	88	167	230	3.15e-20	82.8
k141_127444_6	NCBI|WP_023043165.1|1|1|vanR-D|vanR-D|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|glycopeptide_resistance_response_regulator_transcription_factor_VanR-D|AMR|glycopeptide	38.3	94	167	232	3.26e-20	82.8
k141_127444_6	NCBI|WP_063856727.1|1|1|vanR-D|vanR-D|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|glycopeptide_resistance_response_regulator_transcription_factor_VanR-D|AMR|glycopeptide	38.3	94	167	232	3.26e-20	82.8
k141_127444_6	NCBI|WP_016295750.1|1|1|vanR-D|vanR-D|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|glycopeptide_resistance_response_regulator_transcription_factor_VanR-D|AMR|glycopeptide	38.3	94	167	232	3.26e-20	82.8
k141_127444_6	NCBI|WP_011461303.1|1|1|vanR-I|vanR-I|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|glycopeptide_resistance_response_regulator_transcription_factor_VanR-I|AMR|glycopeptide	45.3	75	167	232	4.56e-20	82.4
k141_127444_6	megares|MEG_7482|Drugs|Glycopeptide|VanL-type_regulator|VANRI_1	45.3	75	167	232	4.56e-20	82.4
k141_127444_10	NCBI|WP_002389535.1|1|1|bcrA_Lm|bcrA_Lm||2|peptide|peptide|peptide_resistance_ABC_transporter_ATP-binding_subunit_BcrA|AMR|peptide	27.4	179	238	307	1.16e-12	65.1
k141_146202_2	SARG|gb|EOD99669.1|ARO:3002875|dfrE	39.8	161	163	164	2.12e-32	112
k141_146202_2	NCBI|WP_038694170.1|1|1|dfrA49|dfrA49|insensitivity|2|diaminopyrimidine|diaminopyrimidine|diaminopyrimidine-resistant_dihydrofolate_reductase_DfrA49|AMR|diaminopyrimidine	39.0	159	163	167	2.30e-32	112
k141_146202_2	SARG|gb|WP_197749399.1|ARO:3005349|DfrA38	41.7	163	163	166	1.79e-31	110
k141_146202_2	SARG|CAE53424	39.5	162	163	169	4.37e-30	106
k141_146202_2	NCBI|WP_004729503.1|1|1|dfrA41|dfrA41|insensitivity|2|diaminopyrimidine|diaminopyrimidine|diaminopyrimidine-resistant_dihydrofolate_reductase_DfrA41|AMR|diaminopyrimidine	33.1	163	163	170	2.51e-26	97.1
k141_146202_2	NCBI|WP_290468344.1|1|1|dfrL|dfrL|insensitivity|2|diaminopyrimidine|diaminopyrimidine|diaminopyrimidine-resistant_dihydrofolate_reductase_DfrL|AMR|diaminopyrimidine	40.3	134	163	176	5.80e-26	96.3
k141_146202_2	CARD|gb|CAC8536249.1|ARO:3007456|dfrL	40.3	134	163	193	8.77e-26	96.3
k141_146202_2	SARG|CAL48457	33.9	165	163	183	3.84e-25	94.4
k141_146202_2	NCBI|WP_434062363.1|1|1|dfrA53|dfrA53|insensitivity|2|diaminopyrimidine|diaminopyrimidine|diaminopyrimidine-resistant_dihydrofolate_reductase_DfrA53|AMR|diaminopyrimidine	36.4	162	163	166	7.87e-24	90.5
k141_146202_2	SARG|gb|AAO04716.1|ARO:3002865|dfrC	36.5	159	163	161	1.09e-22	87.4
k141_3179_11	SARG|gi|505177635|ref|WP_015364737.1|	27.6	438	453	451	1.13e-44	160
k141_3179_11	SARG|ZP_04679156	27.4	438	453	451	5.81e-44	159
k141_3179_11	SARG|gi|446573707|ref|WP_000651053.1|	27.0	429	453	451	1.98e-40	149
k141_3179_11	SARG|gi|488374619|ref|WP_002444004.1|	25.8	438	453	452	2.02e-40	149
k141_3179_11	SARG|gi|686155635|ref|WP_031787393.1|	27.3	429	453	451	3.79e-40	148
k141_3179_11	SARG|gi|446573692|ref|WP_000651038.1|	26.8	429	453	451	3.79e-40	148
k141_3179_11	SARG|gi|565830932|ref|WP_023914633.1|	27.0	429	453	451	5.24e-40	148
k141_3179_11	SARG|gi|493203634|ref|WP_006191797.1|	27.0	429	453	451	5.24e-40	148
k141_3179_11	SARG|gi|486285962|ref|WP_001572033.1|	26.8	429	453	451	5.24e-40	148
k141_3179_11	SARG|gi|487138435|ref|WP_001629863.1|	26.8	429	453	451	5.24e-40	148
k141_13361_9	SARG|gb|APB03219.1|ARO:3003986|TaeA	52.4	649	634	648	3.09e-219	624
k141_13361_9	megares|MEG_4318|Drugs|Multi-drug_resistance|Multi-drug_ABC_efflux_pumps|OPTRA_1	29.0	525	634	655	1.90e-62	218
k141_13361_9	megares|MEG_4308|Drugs|Multi-drug_resistance|Multi-drug_ABC_efflux_pumps|OPTRA_1	28.0	518	634	655	1.90e-62	218
k141_13361_9	megares|MEG_4316|Drugs|Multi-drug_resistance|Multi-drug_ABC_efflux_pumps|OPTRA_1	28.8	525	634	655	2.63e-62	217
k141_13361_9	megares|MEG_4304|Drugs|Multi-drug_resistance|Multi-drug_ABC_efflux_pumps|OPTRA_1	28.8	525	634	655	3.64e-62	217
k141_13361_9	SARG|gb|AKA86814|ARO:3003746|optrA	28.8	525	634	655	3.64e-62	217
k141_13361_9	megares|MEG_4309|Drugs|Multi-drug_resistance|Multi-drug_ABC_efflux_pumps|OPTRA_1	29.0	525	634	655	6.95e-62	216
k141_13361_9	megares|MEG_4306|Drugs|Multi-drug_resistance|Multi-drug_ABC_efflux_pumps|OPTRA_1	29.0	525	634	655	6.95e-62	216
k141_13361_9	megares|MEG_4313|Drugs|Multi-drug_resistance|Multi-drug_ABC_efflux_pumps|OPTRA_1	28.8	525	634	655	2.53e-61	214
k141_13361_9	megares|MEG_4307|Drugs|Multi-drug_resistance|Multi-drug_ABC_efflux_pumps|OPTRA_1	27.8	518	634	655	2.53e-61	214
k141_13361_53	megares|MEG_4091|Drugs|Mupirocin|Mupirocin-resistant_isoleucyl-tRNA_synthetase|MUPB_1	46.2	1039	1040	1033	0.0	927
k141_13361_53	SARG|gb|AEY83581|ARO:3000510|mupB	46.2	1039	1040	1033	0.0	927
k141_13361_53	NCBI|WP_000163435.1|1|1|mupA|mupA|insensitivity|2|mupirocin|mupirocin|mupirocin-resistant_isoleucine--tRNA_ligase_MupA|AMR|mupirocin	44.1	1043	1040	1024	0.0	924
k141_13361_53	megares|MEG_4089|Drugs|Mupirocin|Mupirocin-resistant_isoleucyl-tRNA_synthetase|MUPA_1	44.1	1043	1040	1024	0.0	924
k141_13361_53	megares|MEG_4090|Drugs|Mupirocin|Mupirocin-resistant_isoleucyl-tRNA_synthetase|MUPA_1	45.1	1007	1040	1024	0.0	919
k141_13361_53	SARG|gb|CAA53189|ARO:3000521|mupA	45.1	1007	1040	1024	0.0	919
k141_13361_53	megares|MEG_3295|Drugs|Mupirocin|Mupirocin-resistant_isoleucyl-tRNA_synthetase|ILES_1	36.3	1100	1040	1107	1.63e-221	661
k141_13361_53	SARG|gb|ADP36409.1|ARO:3003730|Bifidobacteria	36.3	1100	1040	1107	1.63e-221	661
k141_13361_55	SARG|gb|AAC74000.1|ARO:3003950|msbA	29.5	539	585	582	6.91e-77	253
k141_13361_55	SARG|gi|664556405|ref|WP_031071225.1|	30.1	489	585	602	6.19e-74	246
k141_13361_55	SARG|gi|501350226|ref|WP_012381861.1|	30.7	486	585	603	3.34e-73	244
k141_13361_55	SARG|gi|928900436|ref|WP_053931243.1|	31.0	493	585	600	6.10e-73	243
k141_13361_55	SARG|gi|664579989|ref|WP_031094015.1|	31.0	493	585	601	6.23e-73	243
k141_13361_55	SARG|gi|490068471|ref|WP_003970646.1|	30.5	486	585	603	2.46e-72	242
k141_13361_55	SARG|gi|664042835|ref|WP_030582300.1|	30.0	486	585	604	2.52e-72	242
k141_13361_55	SARG|gi|948137056|ref|WP_056795395.1|	30.5	489	585	602	4.69e-72	241
k141_13361_55	SARG|gi|664085850|ref|WP_030624018.1|	30.3	489	585	605	6.97e-72	241
k141_13361_55	SARG|gi|664170108|ref|WP_030704355.1|	30.2	486	585	603	9.31e-72	240
k141_13361_56	SARG|gi|505420018|ref|WP_015607120.1|	31.8	554	603	603	3.25e-77	255
k141_13361_56	SARG|gi|695842130|ref|WP_032755430.1|	31.8	554	603	603	4.54e-77	255
k141_13361_56	SARG|gi|517347347|ref|WP_018522839.1|	31.2	557	603	601	8.75e-76	251
k141_13361_56	SARG|gi|948137056|ref|WP_056795395.1|	31.8	557	603	602	8.95e-76	251
k141_13361_56	SARG|gi|926400371|ref|WP_053728483.1|	31.2	570	603	603	3.47e-75	250
k141_13361_56	SARG|gi|664556405|ref|WP_031071225.1|	31.5	571	603	602	6.61e-75	249
k141_13361_56	SARG|gi|663350985|ref|WP_030349761.1|	32.4	556	603	613	8.42e-75	249
k141_13361_56	SARG|gi|664458452|ref|WP_030980047.1|	31.0	562	603	601	9.03e-75	249
k141_13361_56	SARG|gi|558888514|ref|WP_023543283.1|	32.3	567	603	615	1.23e-74	249
k141_13361_56	SARG|gi|1033217078|gb|OAR27197.1|	30.9	572	603	601	1.76e-74	248
k141_13361_57	SARG|gi|960873409|ref|WP_058345546.1|	29.4	211	494	648	2.18e-15	77.8
k141_13361_57	SARG|YP_001571041	29.4	211	494	648	3.84e-15	77.0
k141_13361_57	SARG|gi|555268037|ref|WP_023249477.1|	27.7	202	494	648	3.64e-14	73.9
k141_13361_57	SARG|gi|446048013|ref|WP_000125868.1|	27.0	211	494	648	4.82e-14	73.6
k141_13361_57	SARG|gi|924626178|ref|WP_053530123.1|	27.7	202	494	648	4.82e-14	73.6
k141_13361_57	SARG|gi|1033064422|ref|WP_064375412.1|	27.9	219	494	648	4.82e-14	73.6
k141_13361_57	SARG|gi|924503108|ref|WP_053510027.1|	27.7	202	494	648	4.82e-14	73.6
k141_13361_57	SARG|gi|835330218|ref|WP_047457825.1|	29.2	195	494	648	1.12e-13	72.4
k141_13361_57	SARG|YP_001453760	29.2	195	494	648	1.12e-13	72.4
k141_13361_57	SARG|gi|923061916|ref|WP_053445667.1|	28.3	212	494	648	1.48e-13	72.0
k141_64913_3	CARD|gb|CYF42523.1|ARO:3004047|kdpD	29.6	250	722	885	3.78e-13	72.0
k141_64913_3	CARD|gb|AEX49906.1|ARO:3003583|basS	28.1	249	722	477	5.12e-13	70.9
k141_64913_3	NCBI|WP_063856726.1|1|1|vanR-M|vanR-M|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|glycopeptide_resistance_response_regulator_transcription_factor_VanR-M|AMR|glycopeptide	26.4	125	722	232	1.48e-07	52.0
k141_131613_8	NCBI|XSG12260.1|1|1|drcA|drcA||1|||daptomycin_efflux_ABC_transporter_ATP-binding_protein_DrcA|AMR|peptide	32.1	268	265	255	3.55e-26	102
k141_131613_8	SARG|gi|803568669|ref|WP_046077412.1|	30.3	234	265	648	3.81e-20	88.6
k141_131613_8	SARG|gi|446110352|ref|WP_000188207.1|	30.3	234	265	648	3.81e-20	88.6
k141_131613_8	SARG|YP_002382193	30.3	234	265	648	3.81e-20	88.6
k141_131613_8	SARG|gi|803575554|ref|WP_046081557.1|	30.3	234	265	648	3.81e-20	88.6
k141_131613_8	SARG|gi|446110351|ref|WP_000188206.1|	30.3	234	265	648	3.81e-20	88.6
k141_131613_8	SARG|gi|1035670474|ref|WP_064517458.1|	29.5	234	265	648	7.81e-19	84.7
k141_131613_8	SARG|gi|1035717981|ref|WP_064557480.1|	29.5	234	265	648	7.81e-19	84.7
k141_131613_8	SARG|gi|736472622|ref|WP_034494292.1|	29.5	234	265	648	1.43e-18	84.0
k141_131613_8	SARG|gi|502669352|ref|WP_012905216.1|	27.8	234	265	648	1.93e-18	83.6
k141_131613_26	megares|MEG_1289|Drugs|beta-lactam|Penicillin_binding_protein_regulator|BLAI_1	26.5	113	126	126	1.78e-11	56.2
k141_131613_27	NCBI|WP_012705551.1|1|1|blaR1_gen|blaR1_gen|regulation|2|beta-lactam|beta-lactam|BlaR1_family_beta-lactam_sensor/signal_transducer|AMR|beta-lactam	21.9	334	738	593	5.21e-10	61.6
k141_131613_35	SARG|gb|MBY8651254.1|ARO:3007188|vanH_in_vanP_cl	30.5	203	392	314	1.26e-16	79.0
k141_131613_38	SARG|gi|555251279|ref|WP_023234770.1|	25.5	251	327	372	2.23e-08	53.9
k141_131613_48	SARG|YP_001571041	38.4	232	340	648	5.42e-43	156
k141_131613_48	SARG|gi|960873409|ref|WP_058345546.1|	38.4	232	340	648	1.03e-42	155
k141_131613_48	SARG|gi|740610794|ref|WP_038396317.1|	38.4	232	340	648	2.67e-42	154
k141_131613_48	SARG|gi|835330218|ref|WP_047457825.1|	39.3	242	340	648	3.68e-42	154
k141_131613_48	SARG|YP_001453760	39.3	242	340	648	3.68e-42	154
k141_131613_48	SARG|gi|1035686596|ref|WP_064530178.1|	31.8	305	340	648	6.95e-42	153
k141_131613_48	SARG|gi|740856590|ref|WP_038641842.1|	39.1	220	340	648	1.31e-41	152
k141_131613_48	SARG|gi|922960663|ref|WP_053388845.1|	39.1	220	340	648	1.31e-41	152
k141_131613_48	SARG|gi|757799695|ref|WP_043016897.1|	39.1	220	340	648	1.80e-41	152
k141_131613_48	SARG|gi|974672242|ref|WP_059256507.1|	38.4	229	340	648	1.80e-41	152
k141_131613_56	SARG|gb|WP_011094382.1|ARO:3006903|CAR-1	35.0	100	204	342	9.88e-11	58.9
k141_131613_56	SARG|gb|WP_012145975.1|ARO:3006996|SPR-1	26.4	201	204	298	3.80e-08	51.2
k141_32258_4	SARG|gb|WP_104671188.1|ARO:3003948|efrA	27.7	137	149	575	1.29e-13	65.9
k141_32258_5	SARG|gi|496018010|ref|WP_008742581.1|	46.8	173	400	623	5.37e-43	157
k141_32258_5	SARG|gi|943909899|ref|WP_055545300.1|	41.6	221	400	601	1.12e-42	156
k141_32258_5	SARG|gi|1011969930|ref|WP_062776015.1|	46.8	173	400	601	1.54e-42	156
k141_32258_5	SARG|gi|943896259|ref|WP_055534530.1|	46.2	173	400	601	1.54e-42	156
k141_32258_5	SARG|gi|944152509|ref|WP_055644808.1|	47.1	174	400	616	1.79e-42	156
k141_32258_5	SARG|gi|664244930|ref|WP_030776974.1|	46.2	173	400	601	2.91e-42	155
k141_32258_5	SARG|gi|497748188|ref|WP_010062372.1|	46.8	173	400	605	3.03e-42	155
k141_32258_5	SARG|gi|1045390184|ref|WP_065479071.1|	47.4	173	400	605	3.03e-42	155
k141_32258_5	SARG|gi|516574297|ref|WP_017949361.1|	45.9	185	400	620	3.52e-42	155
k141_32258_5	SARG|gi|517381192|ref|WP_018555350.1|	46.0	174	400	602	7.66e-42	154
k141_32258_10	NCBI|WP_109545033.1|1|1|vanY-D|vanY-D|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|transpeptidase-like_D-Ala-D-Ala_carboxypeptidase_VanY-D|AMR|glycopeptide	37.2	261	518	355	1.39e-44	159
k141_32258_10	megares|MEG_7602|Drugs|Glycopeptide|VanD-type_accessory_protein|VANYD_1	37.2	261	518	355	1.39e-44	159
k141_32258_10	SARG|ACM47285	37.2	261	518	363	1.67e-44	159
k141_32258_10	megares|MEG_7603|Drugs|Glycopeptide|VanD-type_accessory_protein|VANYD_1	36.7	256	518	355	2.60e-42	153
k141_32258_10	SARG|BAE96115	36.7	256	518	355	2.60e-42	153
k141_105685_1	CARD|gb|ALH22601.1|ARO:3000620|adeL	30.8	120	298	337	1.21e-08	54.3
k141_154001_5	CARD|gb|CYF42523.1|ARO:3004047|kdpD	24.1	469	520	885	2.97e-33	133
k141_154001_5	CARD|gb|AAD51347.1|ARO:3003067|smeS	28.1	228	520	467	1.26e-15	78.2
k141_154001_5	NCBI|WP_011461302.1|1|1|vanS-I|vanS-I|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|glycopeptide_resistance_histidine_kinase_VanS-I|AMR|glycopeptide	26.1	234	520	392	2.08e-14	73.9
k141_154001_5	NCBI|WP_028530133.1|1|1|vanS-D|vanS-D|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|glycopeptide_resistance_histidine_kinase_VanS-D|AMR|glycopeptide	27.6	232	520	381	1.10e-13	71.6
k141_154001_5	megares|MEG_7506|Drugs|Glycopeptide|VanD-type_regulator|VANSD_1	27.6	232	520	381	1.10e-13	71.6
k141_154001_5	NCBI|WP_063856744.1|1|1|vanS-D|vanS-D|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|glycopeptide_resistance_histidine_kinase_VanS-D|AMR|glycopeptide	24.9	237	520	381	6.17e-13	69.3
k141_154001_5	megares|MEG_7504|Drugs|Glycopeptide|VanD-type_regulator|VANSD_1	24.9	237	520	381	6.17e-13	69.3
k141_154001_5	megares|MEG_7514|Drugs|Glycopeptide|VanL-type_regulator|VANSL_1	28.9	232	520	364	9.96e-13	68.6
k141_154001_5	NCBI|WP_063856745.1|1|1|vanS-L|vanS-L|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|glycopeptide_resistance_histidine_kinase_VanS-L|AMR|glycopeptide	28.9	232	520	364	9.96e-13	68.6
k141_154001_5	NCBI|WP_063856732.1|1|1|vanS-G|vanS-G|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|glycopeptide_resistance_histidine_kinase_VanS-G|AMR|glycopeptide	26.2	221	520	367	1.80e-12	67.8
k141_154001_6	megares|MEG_3448|Drugs|Aminoglycosides|Aminoglycoside_efflux_pumps|KDPE_1	47.6	225	234	225	1.18e-69	212
k141_154001_6	CARD|gb|AAC73788.1|ARO:3003841|kdpE	47.6	225	234	225	1.18e-69	212
k141_154001_6	NCBI|WP_011461303.1|1|1|vanR-I|vanR-I|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|glycopeptide_resistance_response_regulator_transcription_factor_VanR-I|AMR|glycopeptide	37.2	226	234	232	3.88e-48	157
k141_154001_6	megares|MEG_7482|Drugs|Glycopeptide|VanL-type_regulator|VANRI_1	37.2	226	234	232	3.88e-48	157
k141_154001_6	NCBI|WP_063856718.1|1|1|vanR-E|vanR-E|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|glycopeptide_resistance_response_regulator_transcription_factor_VanR-E|AMR|glycopeptide	34.2	225	234	229	2.01e-47	155
k141_154001_6	NCBI|WP_063856721.1|1|1|vanR-A|vanR-A|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|glycopeptide_resistance_response_regulator_transcription_factor_VanR-A|AMR|glycopeptide	35.0	226	234	231	3.00e-44	147
k141_154001_6	megares|MEG_4078|Drugs|Multi-drug_resistance|Multi-drug_RND_efflux_regulator|MTRAD_1	31.8	223	234	228	3.89e-44	147
k141_154001_6	NCBI|WP_063856728.1|1|1|vanR-N|vanR-N|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|glycopeptide_resistance_response_regulator_transcription_factor_VanR-N|AMR|glycopeptide	33.2	223	234	230	4.11e-44	147
k141_154001_6	NCBI|WP_021418928.1|1|1|vanR-G|vanR-G|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|glycopeptide_resistance_response_regulator_transcription_factor_VanR-G|AMR|glycopeptide	34.3	230	234	235	4.72e-44	147
k141_154001_6	NCBI|WP_003126775.1|1|1|vanR-C|vanR-C|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|glycopeptide_resistance_response_regulator_transcription_factor_VanR-C|AMR|glycopeptide	33.0	224	234	231	5.97e-44	146
k141_134705_2	megares|MEG_5400|Drugs|beta-lactam|Penicillin_binding_protein|PBP2_1	27.1	462	467	633	3.33e-30	122
k141_134705_2	ResF|penA_1_AF515059_1	27.5	429	467	581	3.25e-21	95.5
k141_134705_2	NCBI|WP_049151672.1|1|1|pbp2m|pbp2m||2|beta-lactam|beta-lactam|penicillin-binding_protein_PBP2M|AMR|beta-lactam	26.4	349	467	593	1.41e-20	93.6
k141_134705_13	SARG|YP_002850805	27.9	674	693	652	1.89e-70	241
k141_134705_13	SARG|ZP_02952732	27.3	674	693	652	9.49e-69	236
k141_134705_13	SARG|ZP_02632674	27.3	674	693	660	1.11e-68	236
k141_134705_13	SARG|NP_348076	27.3	666	693	652	1.28e-67	233
k141_134705_13	SARG|L20800.gene.p01	27.2	674	693	652	2.46e-67	232
k141_134705_13	SARG|AAV80410	26.0	655	693	651	3.34e-67	232
k141_134705_13	SARG|L42544.gene.p01	25.6	655	693	651	6.20e-66	228
k141_134705_13	SARG|AJ514254.gene.p01	23.6	675	693	640	1.98e-55	199
k141_134705_13	NCBI|WP_013646121.1|1|1|tet(O/W/32/O)|tet(O/W/32/O)||2|TETRACYCLINE|TETRACYCLINE|tetracycline_resistance_ribosomal_protection_mosaic_protein_Tet(O/W/32/O)|AMR|tetracycline	24.4	663	693	639	5.61e-50	184
k141_134705_13	SARG|ABF69686	24.1	663	693	639	1.05e-49	183
k141_116747_13	NCBI|WP_006285581.1|1|1|vanR-F|vanR-F|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|glycopeptide_resistance_response_regulator_transcription_factor_VanR-F|AMR|glycopeptide	39.3	107	813	231	8.95e-15	73.6
k141_116747_13	NCBI|WP_063856726.1|1|1|vanR-M|vanR-M|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|glycopeptide_resistance_response_regulator_transcription_factor_VanR-M|AMR|glycopeptide	37.5	112	813	232	3.05e-14	72.0
k141_116747_13	CARD|gb|ADM92605.1|ARO:3000553|adeR	33.0	115	813	247	5.86e-09	56.6
k141_116747_13	CARD|gb|AAD51348.1|ARO:3003066|smeR	33.1	118	813	229	2.80e-08	54.3
k141_116747_13	megares|MEG_4290|Drugs|beta-lactam|Mutant_porin_proteins|OMPR_1	27.2	114	813	252	6.49e-08	53.5
k141_90503_43	SARG|ZP_03945515	59.9	272	280	291	2.78e-110	319
k141_90503_43	SARG|ZP_04433866	56.9	269	280	288	9.55e-108	313
k141_90503_43	SARG|ZP_03949893	56.9	269	280	288	9.55e-108	313
k141_90503_43	SARG|ZP_03984017	56.9	269	280	288	9.55e-108	313
k141_90503_43	SARG|ZP_03938934	55.0	269	280	288	2.40e-103	301
k141_90503_43	SARG|ZP_03941859	54.6	269	280	288	9.70e-103	300
k141_90503_43	SARG|YP_002929946	55.3	275	280	282	2.61e-101	296
k141_90503_43	SARG|ZP_03958019	53.7	283	280	317	1.34e-94	280
k141_90503_43	SARG|ZP_04528247	54.2	271	280	279	4.47e-94	278
k141_90503_43	SARG|YP_002937728	53.6	280	280	289	2.88e-92	273
k141_65153_4	megares|MEG_4078|Drugs|Multi-drug_resistance|Multi-drug_RND_efflux_regulator|MTRAD_1	49.8	225	228	228	7.89e-72	217
k141_65153_4	NCBI|WP_063856726.1|1|1|vanR-M|vanR-M|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|glycopeptide_resistance_response_regulator_transcription_factor_VanR-M|AMR|glycopeptide	43.5	230	228	232	1.44e-65	201
k141_65153_4	NCBI|WP_006285581.1|1|1|vanR-F|vanR-F|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|glycopeptide_resistance_response_regulator_transcription_factor_VanR-F|AMR|glycopeptide	43.9	230	228	231	2.27e-64	198
k141_65153_4	NCBI|WP_005228837.1|1|1|vanR-C|vanR-C|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|glycopeptide_resistance_response_regulator_transcription_factor_VanR-C|AMR|glycopeptide	42.5	226	228	231	3.38e-61	190
k141_65153_4	megares|MEG_7449|Drugs|Glycopeptide|VanA-type_regulator|VANRA_1	43.4	226	228	231	9.61e-61	189
k141_65153_4	NCBI|WP_063856716.1|1|1|vanR-A|vanR-A|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|glycopeptide_resistance_response_regulator_transcription_factor_VanR-A|AMR|glycopeptide	43.4	226	228	231	9.61e-61	189
k141_65153_4	NCBI|WP_003126775.1|1|1|vanR-C|vanR-C|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|glycopeptide_resistance_response_regulator_transcription_factor_VanR-C|AMR|glycopeptide	42.4	229	228	231	3.86e-60	187
k141_65153_4	NCBI|WP_011461303.1|1|1|vanR-I|vanR-I|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|glycopeptide_resistance_response_regulator_transcription_factor_VanR-I|AMR|glycopeptide	42.5	228	228	232	5.64e-60	187
k141_65153_4	megares|MEG_7482|Drugs|Glycopeptide|VanL-type_regulator|VANRI_1	42.5	228	228	232	5.64e-60	187
k141_65153_4	NCBI|WP_063856721.1|1|1|vanR-A|vanR-A|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|glycopeptide_resistance_response_regulator_transcription_factor_VanR-A|AMR|glycopeptide	42.9	226	228	231	1.55e-59	186
k141_65153_6	CARD|gb|ABD30512.1|ARO:3000839|arlS	27.0	333	473	451	8.08e-36	137
k141_65153_6	NCBI|WP_063856748.1|1|1|vanS-M|vanS-M|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|glycopeptide_resistance_histidine_kinase_VanS-M|AMR|glycopeptide	28.2	298	473	370	6.20e-33	127
k141_65153_6	NCBI|WP_006285582.1|1|1|vanS-F|vanS-F|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|glycopeptide_resistance_histidine_kinase_VanS-F|AMR|glycopeptide	28.6	262	473	365	1.48e-32	126
k141_65153_6	NCBI|WP_011461302.1|1|1|vanS-I|vanS-I|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|glycopeptide_resistance_histidine_kinase_VanS-I|AMR|glycopeptide	28.6	266	473	392	3.21e-32	125
k141_65153_6	NCBI|WP_063856732.1|1|1|vanS-G|vanS-G|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|glycopeptide_resistance_histidine_kinase_VanS-G|AMR|glycopeptide	32.5	252	473	367	7.51e-32	124
k141_65153_6	NCBI|WP_021418927.1|1|1|vanS-G|vanS-G|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|glycopeptide_resistance_histidine_kinase_VanS-G|AMR|glycopeptide	32.5	249	473	368	1.44e-31	123
k141_65153_6	CARD|gb|ADM92606.1|ARO:3000549|adeS	29.4	296	473	361	7.08e-29	115
k141_65153_6	NCBI|WP_023042297.1|1|1|vanS-D|vanS-D|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|glycopeptide_resistance_histidine_kinase_VanS-D|AMR|glycopeptide	29.5	251	473	381	3.52e-26	108
k141_65153_6	megares|MEG_7509|Drugs|Glycopeptide|VanD-type_regulator|VANSD_1	29.5	251	473	381	3.52e-26	108
k141_65153_6	NCBI|AXB64455.1|1|1|vanS-Cd|vanS-Cd|re-structuring_of_the_cell_wall|1|VANCOMYCIN|GLYCOPEPTIDE|VanG-Cd-type_glycopeptide_resistance_histidine_kinase_VanS|AMR|glycopeptide	31.9	216	473	380	6.43e-26	107
k141_65153_8	CARD|gb|ATC67679.1|ARO:3000838|arlR	51.6	221	229	219	9.31e-74	222
k141_65153_8	megares|MEG_4078|Drugs|Multi-drug_resistance|Multi-drug_RND_efflux_regulator|MTRAD_1	40.1	222	229	228	3.96e-54	172
k141_65153_8	NCBI|WP_006285581.1|1|1|vanR-F|vanR-F|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|glycopeptide_resistance_response_regulator_transcription_factor_VanR-F|AMR|glycopeptide	41.9	222	229	231	2.01e-49	160
k141_65153_8	NCBI|WP_011461303.1|1|1|vanR-I|vanR-I|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|glycopeptide_resistance_response_regulator_transcription_factor_VanR-I|AMR|glycopeptide	37.7	228	229	232	1.65e-48	158
k141_65153_8	megares|MEG_7482|Drugs|Glycopeptide|VanL-type_regulator|VANRI_1	37.7	228	229	232	1.65e-48	158
k141_65153_8	megares|MEG_7449|Drugs|Glycopeptide|VanA-type_regulator|VANRA_1	38.6	228	229	231	2.26e-48	157
k141_65153_8	NCBI|WP_063856716.1|1|1|vanR-A|vanR-A|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|glycopeptide_resistance_response_regulator_transcription_factor_VanR-A|AMR|glycopeptide	38.6	228	229	231	2.26e-48	157
k141_65153_8	NCBI|WP_001280781.1|1|1|vanR-A|vanR-A|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|glycopeptide_resistance_response_regulator_transcription_factor_VanR-A|AMR|glycopeptide	37.7	228	229	231	6.39e-48	156
k141_65153_8	NCBI|WP_063856721.1|1|1|vanR-A|vanR-A|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|glycopeptide_resistance_response_regulator_transcription_factor_VanR-A|AMR|glycopeptide	37.7	228	229	231	9.03e-48	156
k141_65153_8	NCBI|WP_063856720.1|1|1|vanR-A|vanR-A|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|glycopeptide_resistance_response_regulator_transcription_factor_VanR-A|AMR|glycopeptide	37.7	228	229	231	3.60e-47	154
k141_65153_9	CARD|gb|AEX49906.1|ARO:3003583|basS	29.8	255	508	477	4.02e-26	110
k141_132003_6	NCBI|WP_087312253.1|1|1|nimG|nimG||2|NITROIMIDAZOLE|NITROIMIDAZOLE|5-nitroimidazole_reductase_NimG|AMR|nitroimidazole	45.1	153	159	164	1.99e-42	137
k141_132003_6	CARD|gb|CAD56147.1|ARO:3007108|nimF	43.1	153	159	151	1.44e-39	130
k141_132003_6	ResF|nimF_1_AJ515145_1	42.7	157	159	163	1.45e-39	130
k141_132003_6	megares|MEG_4187|Drugs|Metronidazole|nim_nitroimidazole_reductase|NIMH_1	43.8	153	159	152	1.49e-39	130
k141_132003_6	ResF|nimH_1_KX576455_1	43.3	157	159	164	1.49e-39	130
k141_132003_6	CARD|gb|ACR56004.1|ARO:3007110|nimH	43.4	152	159	151	8.23e-39	128
k141_132003_6	NCBI|WP_063854492.1|1|1|nimD|nimD|nitroimidazole_reductase|2|NITROIMIDAZOLE|NITROIMIDAZOLE|5-nitroimidazole_reductase_NimD|AMR|nitroimidazole	41.4	157	159	164	1.37e-37	125
k141_132003_6	NCBI|WP_063854490.1|1|1|nimB|nimB|nitroimidazole_reductase|2|NITROIMIDAZOLE|NITROIMIDAZOLE|5-nitroimidazole_reductase_NimB|AMR|nitroimidazole	41.4	157	159	164	5.52e-37	124
k141_132003_6	NCBI|WP_032488596.1|1|1|nimA|nimA|nitroimidazole_reductase|2|NITROIMIDAZOLE|NITROIMIDAZOLE|5-nitroimidazole_reductase_NimA|AMR|nitroimidazole	41.2	153	159	176	2.20e-36	122
k141_132003_6	NCBI|WP_005812773.1|1|1|nimE|nimE|nitroimidazole_reductase|2|NITROIMIDAZOLE|NITROIMIDAZOLE|5-nitroimidazole_reductase_NimE|AMR|nitroimidazole	40.5	153	159	170	8.48e-35	118
k141_9921_16	SARG|gb|AAC74000.1|ARO:3003950|msbA	30.3	522	592	582	2.01e-68	231
k141_9921_16	SARG|gi|516574297|ref|WP_017949361.1|	32.2	543	592	620	2.29e-66	226
k141_9921_16	SARG|gi|648667297|ref|WP_026359044.1|	31.5	556	592	605	8.86e-66	224
k141_9921_16	SARG|gi|739906046|ref|WP_037756452.1|	31.9	543	592	620	1.19e-65	224
k141_9921_16	SARG|gi|664042835|ref|WP_030582300.1|	31.2	557	592	604	1.68e-65	224
k141_9921_16	SARG|gi|490068471|ref|WP_003970646.1|	31.5	558	592	603	2.29e-65	223
k141_9921_16	SARG|gi|664170108|ref|WP_030704355.1|	31.4	558	592	603	8.52e-65	222
k141_9921_16	SARG|gi|662129758|ref|WP_030081404.1|	31.1	549	592	605	8.86e-65	222
k141_9921_16	SARG|gi|501350226|ref|WP_012381861.1|	31.4	558	592	603	1.18e-64	221
k141_9921_16	SARG|gi|664085850|ref|WP_030624018.1|	31.1	549	592	605	1.23e-64	221
k141_9921_17	SARG|gi|664556405|ref|WP_031071225.1|	29.6	493	577	602	5.98e-66	224
k141_9921_17	SARG|gi|944152509|ref|WP_055644808.1|	28.8	489	577	616	4.05e-63	217
k141_9921_17	SARG|gi|860594225|ref|WP_048475168.1|	27.9	584	577	620	6.06e-63	217
k141_9921_17	SARG|gi|917127754|ref|WP_051734466.1|	27.4	585	577	620	6.06e-63	217
k141_9921_17	SARG|gi|799286378|ref|WP_045936958.1|	27.6	551	577	620	8.41e-63	216
k141_9921_17	SARG|gi|926294973|ref|WP_053631154.1|	27.6	551	577	620	8.41e-63	216
k141_9921_17	SARG|gi|928900436|ref|WP_053931243.1|	28.9	523	577	600	1.12e-62	216
k141_9921_17	SARG|gi|664579989|ref|WP_031094015.1|	28.9	523	577	601	1.14e-62	216
k141_9921_17	SARG|gi|926356413|ref|WP_053687351.1|	27.6	551	577	620	1.17e-62	216
k141_9921_17	SARG|gi|926345639|ref|WP_053677539.1|	27.6	551	577	620	1.17e-62	216
k141_21065_4	SARG|gb|ABA71733.1|ARO:3002972|vanTG	35.9	365	398	712	4.83e-73	240
k141_21065_4	NCBI|CZR78671.1|1|1|vanT-Cd|vanT-Cd|re-structuring_of_the_cell_wall|1|VANCOMYCIN|GLYCOPEPTIDE|membrane-bound_serine_racemase_VanT-Cd|AMR|glycopeptide	34.7	378	398	712	1.09e-65	221
k141_21065_4	NCBI|WP_063856752.1|1|1|vanT-G|vanT-G|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|membrane-bound_serine_racemase_VanT-G|AMR|glycopeptide	33.2	365	398	711	2.84e-59	203
k141_21065_4	NCBI|WP_063856756.1|1|1|vanT-C|vanT-C|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|membrane-bound_serine_racemase_VanT-C|AMR|glycopeptide	34.2	380	398	700	3.13e-55	192
k141_21065_4	SARG|gb|ABX54690.1|ARO:3002974|vanTrL	31.6	373	398	366	1.35e-54	183
k141_21065_4	SARG|JF802084.2.gene3.p01	32.9	343	398	700	1.58e-54	190
k141_21065_4	NCBI|WP_063856755.1|1|1|vanT-C|vanT-C|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|membrane-bound_serine_racemase_VanT-C|AMR|glycopeptide	34.4	343	398	700	4.19e-54	189
k141_21065_4	NCBI|WP_063856759.1|1|1|vanTc3|vanTc3|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|membrane-bound_serine_racemase_VanT|AMR|glycopeptide	33.8	343	398	700	4.03e-53	186
k141_21065_4	NCBI|WP_063856758.1|1|1|vanTc2|vanTc2|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|membrane-bound_serine_racemase_VanT|AMR|glycopeptide	33.5	343	398	706	4.12e-52	184
k141_21065_4	SARG|gi|498467693|ref|WP_010773049.1|	32.4	343	398	700	2.67e-51	181
k141_21065_7	megares|MEG_4304|Drugs|Multi-drug_resistance|Multi-drug_ABC_efflux_pumps|OPTRA_1	32.6	491	519	655	4.95e-82	267
k141_21065_7	SARG|gb|AKA86814|ARO:3003746|optrA	32.6	491	519	655	4.95e-82	267
k141_21065_7	megares|MEG_4313|Drugs|Multi-drug_resistance|Multi-drug_ABC_efflux_pumps|OPTRA_1	32.6	491	519	655	9.69e-82	266
k141_21065_7	megares|MEG_4312|Drugs|Multi-drug_resistance|Multi-drug_ABC_efflux_pumps|OPTRA_1	32.6	491	519	655	9.69e-82	266
k141_21065_7	megares|MEG_4306|Drugs|Multi-drug_resistance|Multi-drug_ABC_efflux_pumps|OPTRA_1	32.4	491	519	655	9.69e-82	266
k141_21065_7	megares|MEG_4315|Drugs|Multi-drug_resistance|Multi-drug_ABC_efflux_pumps|OPTRA_1	32.6	491	519	655	9.69e-82	266
k141_21065_7	megares|MEG_4307|Drugs|Multi-drug_resistance|Multi-drug_ABC_efflux_pumps|OPTRA_1	32.6	491	519	655	1.36e-81	266
k141_21065_7	megares|MEG_4323|Drugs|Multi-drug_resistance|Multi-drug_ABC_efflux_pumps|OPTRA_1	32.6	491	519	655	1.90e-81	265
k141_21065_7	megares|MEG_4309|Drugs|Multi-drug_resistance|Multi-drug_ABC_efflux_pumps|OPTRA_1	32.4	491	519	655	3.72e-81	265
k141_21065_7	megares|MEG_4318|Drugs|Multi-drug_resistance|Multi-drug_ABC_efflux_pumps|OPTRA_1	32.4	491	519	655	7.27e-81	264
k141_128076_11	megares|MEG_5400|Drugs|beta-lactam|Penicillin_binding_protein|PBP2_1	32.4	376	946	633	9.47e-35	140
k141_128076_11	SARG|gb|AQX82857.1|ARO:3004185|mecD	31.2	138	946	678	5.72e-07	52.4
k141_128076_11	ResF|penA_1_AF515059_1	28.8	118	946	581	2.09e-06	50.4
k141_128076_26	NCBI|ACF30254.1|1|1|mtrR|mtrR|efflux|1|EFFLUX|EFFLUX|multidrug_efflux_system_transcriptional_repressor_MtrR|AMR|efflux	20.9	196	202	210	3.17e-06	45.1
k141_128076_44	megares|MEG_4091|Drugs|Mupirocin|Mupirocin-resistant_isoleucyl-tRNA_synthetase|MUPB_1	22.9	280	660	1033	7.82e-08	54.7
k141_128076_44	SARG|gb|AEY83581|ARO:3000510|mupB	22.9	280	660	1033	7.82e-08	54.7
k141_128076_44	megares|MEG_3295|Drugs|Mupirocin|Mupirocin-resistant_isoleucyl-tRNA_synthetase|ILES_1	26.0	273	660	1107	1.37e-07	53.9
k141_128076_44	SARG|gb|ADP36409.1|ARO:3003730|Bifidobacteria	26.0	273	660	1107	1.37e-07	53.9
k141_50704_3	NCBI|WP_006285581.1|1|1|vanR-F|vanR-F|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|glycopeptide_resistance_response_regulator_transcription_factor_VanR-F|AMR|glycopeptide	30.0	120	492	231	4.72e-12	64.7
k141_50704_3	megares|MEG_7514|Drugs|Glycopeptide|VanL-type_regulator|VANSL_1	22.5	253	492	364	5.07e-12	66.2
k141_50704_3	NCBI|WP_063856745.1|1|1|vanS-L|vanS-L|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|glycopeptide_resistance_histidine_kinase_VanS-L|AMR|glycopeptide	22.5	253	492	364	5.07e-12	66.2
k141_50704_3	NCBI|WP_222891058.1|1|1|vanS-P|vanS-P|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|glycopeptide_resistance_histidine_kinase_VanS-P|AMR|glycopeptide	21.1	246	492	359	2.77e-11	63.9
k141_50704_3	CARD|gb|AEX49906.1|ARO:3003583|basS	25.5	286	492	477	7.24e-11	63.2
k141_50704_3	NCBI|WP_063856726.1|1|1|vanR-M|vanR-M|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|glycopeptide_resistance_response_regulator_transcription_factor_VanR-M|AMR|glycopeptide	30.8	117	492	232	6.24e-09	55.5
k141_50704_3	CARD|gb|ATC67679.1|ARO:3000838|arlR	28.1	135	492	219	2.75e-06	47.4
k141_50704_3	CARD|gb|AAG06465.1|ARO:3005063|cprR	30.6	121	492	223	3.83e-06	47.0
k141_50704_3	megares|MEG_4078|Drugs|Multi-drug_resistance|Multi-drug_RND_efflux_regulator|MTRAD_1	26.4	125	492	228	9.67e-06	45.8
k141_61826_4	SARG|gi|505420018|ref|WP_015607120.1|	30.2	245	266	603	8.74e-23	96.3
k141_61826_4	SARG|gi|817122037|ref|WP_046494699.1|	32.0	225	266	613	2.20e-22	95.1
k141_61826_4	SARG|gi|558888514|ref|WP_023543283.1|	32.2	230	266	615	2.20e-22	95.1
k141_61826_4	SARG|AF170880.4.gene1.p01	31.7	230	266	615	5.48e-22	94.0
k141_61826_4	SARG|gi|695842130|ref|WP_032755430.1|	29.8	245	266	603	1.35e-21	92.8
k141_61826_4	SARG|gi|695865802|ref|WP_032778631.1|	30.6	245	266	605	1.35e-21	92.8
k141_61826_4	SARG|gi|663350985|ref|WP_030349761.1|	30.9	220	266	613	1.36e-21	92.8
k141_61826_4	SARG|gi|739906046|ref|WP_037756452.1|	31.6	225	266	620	1.37e-21	92.8
k141_61826_4	SARG|gi|516574297|ref|WP_017949361.1|	31.6	225	266	620	1.85e-21	92.4
k141_61826_4	SARG|gi|947982677|ref|WP_056642336.1|	30.4	237	266	626	1.86e-21	92.4
k141_61826_7	CARD|gb|ATC67679.1|ARO:3000838|arlR	48.3	178	226	219	2.00e-51	165
k141_61826_7	megares|MEG_4078|Drugs|Multi-drug_resistance|Multi-drug_RND_efflux_regulator|MTRAD_1	42.6	223	226	228	5.21e-51	164
k141_61826_7	CARD|gb|AAG05188.1|ARO:3005068|ParR	43.0	221	226	235	1.44e-49	160
k141_61826_7	NCBI|WP_002317273.1|1|1|vanR-B|vanR-B|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|glycopeptide_resistance_response_regulator_transcription_factor_VanR-B|AMR|glycopeptide	42.5	219	226	219	1.02e-48	158
k141_61826_7	NCBI|WP_063856719.1|1|1|vanR-B|vanR-B|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|glycopeptide_resistance_response_regulator_transcription_factor_VanR-B|AMR|glycopeptide	42.5	219	226	220	1.05e-48	158
k141_61826_7	NCBI|WP_032489743.1|1|1|vanR-B|vanR-B|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|glycopeptide_resistance_response_regulator_transcription_factor_VanR-B|AMR|glycopeptide	42.5	219	226	220	1.49e-48	157
k141_61826_7	NCBI|WP_002368697.1|1|1|vanR-B|vanR-B|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|glycopeptide_resistance_response_regulator_transcription_factor_VanR-B|AMR|glycopeptide	43.5	223	226	220	1.49e-48	157
k141_61826_7	NCBI|WP_063856723.1|1|1|vanR-B|vanR-B|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|glycopeptide_resistance_response_regulator_transcription_factor_VanR-B|AMR|glycopeptide	42.0	219	226	219	8.19e-48	155
k141_61826_7	NCBI|WP_011461303.1|1|1|vanR-I|vanR-I|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|glycopeptide_resistance_response_regulator_transcription_factor_VanR-I|AMR|glycopeptide	38.4	229	226	232	8.45e-45	148
k141_61826_7	megares|MEG_7482|Drugs|Glycopeptide|VanL-type_regulator|VANRI_1	38.4	229	226	232	8.45e-45	148
k141_61826_8	NCBI|WP_028530133.1|1|1|vanS-D|vanS-D|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|glycopeptide_resistance_histidine_kinase_VanS-D|AMR|glycopeptide	27.8	230	555	381	8.87e-23	99.4
k141_61826_8	megares|MEG_7506|Drugs|Glycopeptide|VanD-type_regulator|VANSD_1	27.8	230	555	381	8.87e-23	99.4
k141_61826_8	megares|MEG_7505|Drugs|Glycopeptide|VanD-type_regulator|VANSD_1	27.8	230	555	381	1.19e-22	99.0
k141_61826_8	NCBI|WP_063856730.1|1|1|vanS-D|vanS-D|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|glycopeptide_resistance_histidine_kinase_VanS-D|AMR|glycopeptide	27.8	230	555	381	1.19e-22	99.0
k141_61826_8	NCBI|WP_023042297.1|1|1|vanS-D|vanS-D|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|glycopeptide_resistance_histidine_kinase_VanS-D|AMR|glycopeptide	27.4	230	555	381	2.92e-22	97.8
k141_61826_8	megares|MEG_7509|Drugs|Glycopeptide|VanD-type_regulator|VANSD_1	27.4	230	555	381	2.92e-22	97.8
k141_61826_8	CARD|gb|BAB38260.1|ARO:3000830|cpxA	30.3	221	555	457	6.03e-21	94.7
k141_61826_8	NCBI|WP_006285582.1|1|1|vanS-F|vanS-F|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|glycopeptide_resistance_histidine_kinase_VanS-F|AMR|glycopeptide	27.0	226	555	365	1.23e-19	89.7
k141_61826_8	NCBI|WP_063856748.1|1|1|vanS-M|vanS-M|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|glycopeptide_resistance_histidine_kinase_VanS-M|AMR|glycopeptide	26.8	224	555	370	2.45e-18	85.9
k141_61826_8	CARD|gb|CYF42523.1|ARO:3004047|kdpD	26.7	206	555	885	1.09e-14	76.3
k141_57761_3	SARG|gb|AYV52072.1|ARO:3002882|lmrD	30.1	236	249	664	9.02e-20	87.0
k141_57761_3	megares|MEG_4383|Drugs|Tetracycline|Tetracycline_resistance_ABC_efflux_pumps|OTRC_1	23.8	227	249	351	7.07e-15	72.0
k141_57761_3	SARG|gb|AAR96051.1|ARO:3002894|otrC	23.8	227	249	351	1.31e-14	71.2
k141_57761_5	SARG|gb|ATL63235.1|ARO:3004357|catV	38.2	199	216	219	2.01e-51	164
k141_57761_5	SARG|gb|APB03217.1|ARO:3003983|CatU	38.2	204	216	217	1.96e-48	157
k141_57761_5	SARG|NC_002096.2598307.p01	30.5	203	216	215	1.32e-36	126
k141_57761_5	SARG|X02529.1.gene3.p1	31.2	199	216	215	2.63e-36	125
k141_57761_5	SARG|X02872.1.gene2.p1	30.5	203	216	215	2.63e-36	125
k141_57761_5	SARG|M64281.gene.p01	30.7	199	216	215	1.46e-35	124
k141_57761_5	SARG|X60827.1.gene2.p01	31.2	199	216	215	1.46e-35	124
k141_57761_5	SARG|M90091.1.gene2.p01	29.8	198	216	215	5.79e-35	122
k141_57761_5	SARG|YP_001429537	29.8	198	216	215	5.79e-35	122
k141_57761_5	SARG|U83488.1.gene4.p01	30.2	199	216	215	5.79e-35	122
k141_21485_11	NCBI|WP_000163435.1|1|1|mupA|mupA|insensitivity|2|mupirocin|mupirocin|mupirocin-resistant_isoleucine--tRNA_ligase_MupA|AMR|mupirocin	25.2	827	878	1024	1.70e-65	236
k141_21485_11	megares|MEG_4089|Drugs|Mupirocin|Mupirocin-resistant_isoleucyl-tRNA_synthetase|MUPA_1	25.2	827	878	1024	1.70e-65	236
k141_21485_11	megares|MEG_4090|Drugs|Mupirocin|Mupirocin-resistant_isoleucyl-tRNA_synthetase|MUPA_1	25.2	827	878	1024	5.68e-65	235
k141_21485_11	SARG|gb|CAA53189|ARO:3000521|mupA	25.2	827	878	1024	5.68e-65	235
k141_21485_11	megares|MEG_4091|Drugs|Mupirocin|Mupirocin-resistant_isoleucyl-tRNA_synthetase|MUPB_1	26.2	596	878	1033	6.40e-56	208
k141_21485_11	SARG|gb|AEY83581|ARO:3000510|mupB	26.2	596	878	1033	6.40e-56	208
k141_21485_15	megares|MEG_7571|Drugs|Glycopeptide|VanM-type_resistance_protein|VANXM_2	36.9	458	462	451	4.60e-84	265
k141_21485_15	megares|MEG_7572|Drugs|Glycopeptide|VanM-type_resistance_protein|VANXM_2	36.7	460	462	481	5.79e-83	263
k141_21485_15	megares|MEG_7563|Drugs|Glycopeptide|VanB-type_resistance_protein|VANXB_2	35.4	458	462	451	1.10e-81	258
k141_21485_18	NCBI|WP_049151672.1|1|1|pbp2m|pbp2m||2|beta-lactam|beta-lactam|penicillin-binding_protein_PBP2M|AMR|beta-lactam	27.5	324	748	593	7.94e-23	102
k141_114408_2	SARG|gi|895981299|ref|WP_049056431.1|	35.4	240	255	648	3.14e-38	140
k141_114408_2	SARG|gi|823281237|ref|WP_047037467.1|	35.4	240	255	648	3.14e-38	140
k141_114408_2	SARG|gi|895967513|ref|WP_049046752.1|	35.4	240	255	648	3.14e-38	140
k141_114408_2	SARG|gi|779903733|ref|WP_045374054.1|	35.4	240	255	648	3.14e-38	140
k141_114408_2	SARG|gi|639225329|ref|WP_024561799.1|	38.1	231	255	648	1.40e-36	135
k141_114408_2	SARG|gi|639218559|ref|WP_024556062.1|	38.1	231	255	648	1.40e-36	135
k141_114408_2	SARG|gi|657888313|ref|WP_029592374.1|	37.7	231	255	648	4.93e-36	134
k141_114408_2	SARG|gi|896325272|ref|WP_049294291.1|	36.8	231	255	648	4.93e-36	134
k141_114408_2	SARG|gi|639216333|ref|WP_024554080.1|	35.6	239	255	648	9.25e-36	133
k141_77460_1	NCBI|WP_109545033.1|1|1|vanY-D|vanY-D|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|transpeptidase-like_D-Ala-D-Ala_carboxypeptidase_VanY-D|AMR|glycopeptide	29.5	288	465	355	3.86e-28	113
k141_77460_1	megares|MEG_7602|Drugs|Glycopeptide|VanD-type_accessory_protein|VANYD_1	29.5	288	465	355	3.86e-28	113
k141_77460_1	SARG|ACM47285	29.5	288	465	363	4.38e-28	113
k141_77460_1	megares|MEG_7603|Drugs|Glycopeptide|VanD-type_accessory_protein|VANYD_1	29.5	288	465	355	5.28e-28	113
k141_77460_1	SARG|BAE96115	29.5	288	465	355	5.28e-28	113
k141_77460_1	NCBI|WP_049898469.1|1|1|vanY-D|vanY-D|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|transpeptidase-like_D-Ala-D-Ala_carboxypeptidase_VanY-D|AMR|glycopeptide	31.5	260	465	356	1.37e-27	112
k141_77460_1	NCBI|WP_063856871.1|1|1|vanY-D|vanY-D|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|transpeptidase-like_D-Ala-D-Ala_carboxypeptidase_VanY-D|AMR|glycopeptide	30.3	290	465	346	2.19e-27	111
k141_77460_1	NCBI|WP_063856862.1|1|1|vanY-D|vanY-D|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|transpeptidase-like_D-Ala-D-Ala_carboxypeptidase_VanY-D|AMR|glycopeptide	30.4	260	465	356	1.22e-26	109
k141_77460_1	NCBI|WP_063856854.1|1|1|vanY-D|vanY-D|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|transpeptidase-like_D-Ala-D-Ala_carboxypeptidase_VanY-D|AMR|glycopeptide	31.5	260	465	356	1.67e-26	108
k141_77460_1	megares|MEG_7604|Drugs|Glycopeptide|VanD-type_accessory_protein|VANYD_2	32.8	198	465	209	9.06e-21	89.4
k141_77460_4	SARG|gi|663330365|ref|WP_030329892.1|	26.3	213	258	607	8.76e-13	66.6
k141_77460_4	SARG|gi|662175949|ref|WP_030118884.1|	26.3	205	258	605	1.18e-12	66.2
k141_77460_4	SARG|gi|663155409|ref|WP_030194633.1|	26.3	205	258	605	1.18e-12	66.2
k141_77460_4	SARG|gi|664538723|ref|WP_031054357.1|	26.3	205	258	605	1.18e-12	66.2
k141_77460_4	SARG|gi|764446018|ref|WP_044369325.1|	25.4	213	258	605	2.14e-12	65.5
k141_77460_4	SARG|gi|695887424|ref|WP_032788534.1|	25.4	213	258	605	2.87e-12	65.1
k141_77460_4	SARG|gi|695865802|ref|WP_032778631.1|	25.4	213	258	605	2.87e-12	65.1
k141_77460_4	SARG|gi|664180077|ref|WP_030714054.1|	25.4	213	258	605	2.87e-12	65.1
k141_77460_4	SARG|gi|1045390184|ref|WP_065479071.1|	24.9	213	258	605	5.21e-12	64.3
k141_77460_4	SARG|gi|1033151784|ref|WP_064457526.1|	26.1	211	258	614	5.24e-12	64.3
k141_77460_15	SARG|CAA37477	27.6	493	525	663	8.66e-36	140
k141_77460_15	SARG|AAR29485	27.1	462	525	639	5.11e-34	135
k141_77460_15	SARG|gi|544707441|ref|WP_021137831.1|	27.1	462	525	639	5.11e-34	135
k141_77460_15	SARG|AJ295238.gene.p01	27.2	448	525	639	5.61e-33	132
k141_77460_15	SARG|gi|672386269|gb|AIJ27535.1|	26.8	462	525	639	5.61e-33	132
k141_77460_15	megares|MEG_7170|Drugs|Tetracycline|Tetracycline_resistance_ribosomal_protection_proteins|TETO_1	27.4	474	525	629	7.18e-33	131
k141_77460_15	megares|MEG_7173|Drugs|Tetracycline|Tetracycline_resistance_ribosomal_protection_proteins|TETO_1	27.5	461	525	629	7.18e-33	131
k141_77460_15	SARG|gi|254621978|gb|ACT76131.1|	26.8	462	525	639	7.56e-33	131
k141_77460_15	ResF|tet(O/W)_1_AM889118_1	27.5	461	525	639	7.56e-33	131
k141_77460_15	ResF|tet(O/W)_4_AM889121_1	27.4	474	525	639	7.56e-33	131
k141_172504_1	megares|MEG_4306|Drugs|Multi-drug_resistance|Multi-drug_ABC_efflux_pumps|OPTRA_1	38.1	643	640	655	1.17e-128	392
k141_172504_1	megares|MEG_4309|Drugs|Multi-drug_resistance|Multi-drug_ABC_efflux_pumps|OPTRA_1	37.9	643	640	655	1.83e-127	389
k141_172504_1	megares|MEG_4323|Drugs|Multi-drug_resistance|Multi-drug_ABC_efflux_pumps|OPTRA_1	37.8	643	640	655	3.62e-127	389
k141_172504_1	megares|MEG_4316|Drugs|Multi-drug_resistance|Multi-drug_ABC_efflux_pumps|OPTRA_1	37.8	643	640	655	3.62e-127	389
k141_172504_1	megares|MEG_4311|Drugs|Multi-drug_resistance|Multi-drug_ABC_efflux_pumps|OPTRA_1	37.8	643	640	655	3.62e-127	389
k141_172504_1	megares|MEG_4305|Drugs|Multi-drug_resistance|Multi-drug_ABC_efflux_pumps|OPTRA_1	37.8	643	640	655	3.62e-127	389
k141_172504_1	megares|MEG_4321|Drugs|Multi-drug_resistance|Multi-drug_ABC_efflux_pumps|OPTRA_1	37.8	643	640	655	5.10e-127	388
k141_172504_1	megares|MEG_4317|Drugs|Multi-drug_resistance|Multi-drug_ABC_efflux_pumps|OPTRA_1	37.8	643	640	655	5.10e-127	388
k141_172504_1	megares|MEG_4314|Drugs|Multi-drug_resistance|Multi-drug_ABC_efflux_pumps|OPTRA_1	37.8	643	640	655	5.10e-127	388
k141_172504_1	megares|MEG_4319|Drugs|Multi-drug_resistance|Multi-drug_ABC_efflux_pumps|OPTRA_1	37.8	643	640	655	5.10e-127	388
k141_172504_3	SARG|gb|AML99881.1|ARO:3001327|mdtK	30.2	457	453	474	2.63e-59	200
k141_172504_21	NCBI|WP_003126775.1|1|1|vanR-C|vanR-C|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|glycopeptide_resistance_response_regulator_transcription_factor_VanR-C|AMR|glycopeptide	30.6	124	262	231	1.20e-08	53.1
k141_172504_21	NCBI|WP_005228837.1|1|1|vanR-C|vanR-C|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|glycopeptide_resistance_response_regulator_transcription_factor_VanR-C|AMR|glycopeptide	29.0	124	262	231	2.20e-08	52.4
k141_172504_21	NCBI|WP_063856725.1|1|1|vanR-C|vanR-C|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|glycopeptide_resistance_response_regulator_transcription_factor_VanR-C|AMR|glycopeptide	29.0	124	262	231	2.98e-08	52.0
k141_172504_21	NCBI|WP_034872470.1|1|1|vanR-C|vanR-C|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|glycopeptide_resistance_response_regulator_transcription_factor_VanR-C|AMR|glycopeptide	29.0	124	262	231	4.04e-08	51.6
k141_172504_21	NCBI|WP_023043165.1|1|1|vanR-D|vanR-D|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|glycopeptide_resistance_response_regulator_transcription_factor_VanR-D|AMR|glycopeptide	28.0	132	262	232	1.01e-07	50.4
k141_172504_21	NCBI|WP_063856722.1|1|1|vanR-D|vanR-D|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|glycopeptide_resistance_response_regulator_transcription_factor_VanR-D|AMR|glycopeptide	28.0	132	262	232	3.35e-07	48.9
k141_172504_22	SARG|gb|ANZ79476.1|ARO:3003908|Erm(47)	31.1	183	293	246	5.46e-21	88.6
k141_172504_22	SARG|L22689.1.gene1.p01	29.7	182	293	257	2.06e-17	79.0
k141_172504_22	SARG|gb|CZT31773.1|ARO:3004094|Erm(48)	28.0	200	293	243	2.13e-16	75.9
k141_172504_22	NCBI|WP_052259183.1|1|1|erm(42)|erm(42)|target_modification|2|CLINDAMYCIN/ERYTHROMYCIN|LINCOSAMIDE/MACROLIDE|23S_rRNA_(adenine(2058)-N(6))-methyltransferase_Erm(42)|AMR|multidrug	30.7	150	293	301	1.76e-12	65.5
k141_172504_22	megares|MEG_2781|Drugs|MLS|23S_rRNA_methyltransferases|ERM42_1	30.7	150	293	303	1.78e-12	65.5
k141_172504_22	SARG|gb|CBY77552.1|ARO:3003106|Erm(42)	30.7	150	293	301	3.22e-12	64.7
k141_169259_4	CARD|gb|AAC75429.1|ARO:3000833|evgS	30.9	372	639	1197	2.28e-44	169
k141_169259_4	NCBI|WP_222891058.1|1|1|vanS-P|vanS-P|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|glycopeptide_resistance_histidine_kinase_VanS-P|AMR|glycopeptide	25.7	226	639	359	9.74e-16	78.2
k141_169259_4	CARD|gb|AEX49906.1|ARO:3003583|basS	27.6	232	639	477	6.14e-15	76.6
k141_169259_4	megares|MEG_7514|Drugs|Glycopeptide|VanL-type_regulator|VANSL_1	26.5	230	639	364	1.85e-14	74.3
k141_169259_4	NCBI|WP_063856745.1|1|1|vanS-L|vanS-L|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|glycopeptide_resistance_histidine_kinase_VanS-L|AMR|glycopeptide	26.5	230	639	364	1.85e-14	74.3
k141_169259_4	CARD|gb|ADM92605.1|ARO:3000553|adeR	35.0	120	639	247	6.81e-11	62.0
k141_169259_4	NCBI|WP_006285581.1|1|1|vanR-F|vanR-F|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|glycopeptide_resistance_response_regulator_transcription_factor_VanR-F|AMR|glycopeptide	33.6	107	639	231	7.41e-11	61.6
k141_169259_4	NCBI|WP_063856726.1|1|1|vanR-M|vanR-M|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|glycopeptide_resistance_response_regulator_transcription_factor_VanR-M|AMR|glycopeptide	32.5	114	639	232	2.48e-10	60.1
k141_62516_8	CARD|gb|AAN28945.1|ARO:3003785|Ctra_murA_FOF	36.6	426	421	444	1.15e-64	213
k141_147298_3	CARD|gb|AAC75136.1|ARO:3000793|mdtB	28.4	1017	1052	1040	1.20e-106	356
k141_147298_3	SARG|YP_350221	27.0	1017	1052	1009	1.71e-98	333
k141_147298_3	SARG|CAY51926	26.9	1013	1052	1008	3.20e-98	332
k141_147298_3	CARD|gb|AAC75137.1|ARO:3000794|mdtC	27.1	1028	1052	1025	8.08e-98	332
k141_147298_3	SARG|YP_001266290	26.9	1017	1052	1014	4.00e-95	324
k141_147298_3	SARG|gb|AAG05915.1|ARO:3004074|MuxB	26.7	1028	1052	1043	6.33e-95	324
k141_147298_3	SARG|YP_001670703	26.6	1029	1052	1014	5.10e-94	321
k141_147298_3	SARG|YP_001186705	25.7	1011	1052	1017	2.62e-93	319
k141_147298_3	CARD|gb|AAL14440.1|ARO:3000775|adeB	27.2	1042	1052	1035	1.69e-92	317
k141_147298_3	SARG|YP_606823	26.5	1020	1052	1011	1.47e-91	314
k141_147298_4	SARG|CP000768.1.gene1024.p01	21.6	375	370	390	2.04e-15	75.9
k141_147298_4	SARG|gi|533111866|ref|WP_020975044.1|	21.6	338	370	390	6.64e-15	74.3
k141_147298_4	CARD|gb|AAG03547.1|ARO:3003680|TriB	22.2	288	370	356	8.24e-13	67.8
k141_147298_4	SARG|gi|489018151|ref|WP_002928665.1|	22.6	199	370	380	9.54e-10	58.5
k141_147298_4	SARG|gi|488875110|ref|WP_002787335.1|	23.0	209	370	390	9.82e-10	58.5
k141_147298_4	SARG|gi|488864031|ref|WP_002776270.1|	23.0	209	370	390	9.82e-10	58.5
k141_147298_4	SARG|gi|488931692|ref|WP_002842767.1|	23.0	209	370	390	9.82e-10	58.5
k141_147298_4	SARG|gi|488918619|ref|WP_002829694.1|	23.0	209	370	390	9.82e-10	58.5
k141_147298_4	SARG|gi|490445525|ref|WP_004316446.1|	22.0	209	370	390	2.32e-09	57.4
k141_147298_4	SARG|gi|490435709|ref|WP_004306762.1|	22.0	209	370	390	3.09e-09	57.0
k141_91808_4	SARG|gb|AYV52072.1|ARO:3002882|lmrD	27.9	215	243	664	5.27e-23	96.3
k141_91808_4	SARG|gb|AAR96051.1|ARO:3002894|otrC	25.7	241	243	351	5.37e-19	83.6
k141_91808_4	megares|MEG_4383|Drugs|Tetracycline|Tetracycline_resistance_ABC_efflux_pumps|OTRC_1	28.0	225	243	351	1.90e-18	82.0
k141_91808_4	SARG|gb|ANZ79240.1|ARO:3004035|tetA(60)	29.4	214	243	579	9.53e-18	80.9
k141_91808_4	NCBI|WP_289811734.1|1|1|tetA(60)|tetA(60)||2|TETRACYCLINE|TETRACYCLINE|tetracycline_efflux_ABC_transporter_Tet(60)_subunit_A|AMR|tetracycline	29.0	214	243	579	4.33e-17	79.0
k141_91808_4	SARG|gb|AAC75271.1|ARO:3003952|yojI	30.5	203	243	547	1.44e-13	68.6
k141_91808_4	NCBI|WP_011116970.1|1|1|tetAB_B|tetAB_B|efflux|2|TETRACYCLINE|TETRACYCLINE|tetracycline_efflux_ABC_transporter_TetAB_subunit_B|AMR|tetracycline	27.4	215	243	528	8.58e-13	66.2
k141_91808_6	CARD|gb|AAK37618.1|ARO:3005008|TxR	38.7	318	475	318	3.37e-60	199
k141_66118_5	NCBI|WP_005480402.1|1|1|tet(35)|tet(35)|efflux|2|TETRACYCLINE|TETRACYCLINE|tetracycline_efflux_Na+/H+_antiporter_family_transporter_Tet(35)|AMR|tetracycline	38.2	524	553	533	4.42e-101	314
k141_66118_5	SARG|AF353562.gene.p01	34.9	370	553	369	4.30e-57	194
k141_169753_7	megares|MEG_6058|Drugs|MLS|23S_rRNA_methyltransferases|RLMH_1	59.1	159	160	159	1.64e-62	188
